

Annual Report & Accounts 2015 - 2016



**EAST INDIA PHARMACEUTICAL
WORKS LIMITED**

Contents

Board of Directors	2
A Decade at a Glance	3
Directors' Report	4
Independent Auditors' Report	22
Balance Sheet	28
Statement of Profit & Loss	29
Cash Flow Statement	30
Notes	31
Consolidated Financial Statements alongwith Independent Auditors' Report	44
EAST INDIA Organisation	65
Names & Addresses of C & F Agents	67



Board of Directors

Dr. Ranabir Mukherji
Mr. Dilip Samadar
Mr. Probir Roy
Prof. (Dr.) Suman Kumar Mukerjee
Prof. (Dr.) Himadri Sengupta
Mr. Sukamal Chandra Basu

Mr. Chiraranjan Addy
Dr. Abhijit Banerjee
Dr. Tapas Raychaudhury
Mr. Amit Kumar Sen (Managing Director)
Mr. Debarshi Duttagupta (Managing Director)

Secretary & Chief Compliance Officer

Mr. Nirjhar Mukhopadhyay

Chief Financial Officer

Mr. Subrata Ray

Statutory Auditors

M/s APS Associates
Chartered Accountants
3-C, Madan Street, 1st Floor
Kolkata 700 072

Cost Auditors

M/s DGM & Associates
Cost Accountants
64, B. B. Ganguly Street, (2nd. Floor),
Kolkata 700 012

Principal Banker

United Bank of India
Hazra Road Branch
53, S. P. Mukherjee Road, Kolkata 700 026

Bankers

Andhra Bank, AXIS Bank Ltd., HSBC Limited, Bank of Baroda, Bank of India, Central Bank of India, HDFC Bank Ltd., Indian Bank, Indian Overseas Bank, Kotak Mahindra Bank, Punjab National Bank, State Bank of India, State Bank of Travancore, The Kapol Co-operative Bank Ltd. & Union Bank of India.

Registered Office

6, Nandalal Bose Sarani, Kolkata 700 071
CIN : U24231WB1936PLC008598
Website : www.eastindiapharma.org

A Decade At A Glance

	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Fixed Assets	1605.25	1088.12	1103.69	1260.99	1402.34	1367.92	1401.32	1518.51	1514.75	1369.35
Current Assets, Loans & Advances	10258.31	9599.97	9176.10	8008.28	7220.88	6885.54	6191.97	5389.37	5025.11	4173.80
Share Capital	667.45	667.45	667.45	667.45	667.45*	444.97	444.97	444.97	444.97	444.97
Reserves & Surplus	3395.23	3113.55	2980.59	2751.12	2907.45	2857.42	2540.97	2329.62	2142.00	2004.33
Loans	2765.10	2223.47	2247.17	2449.85	2211.66	2086.67	2020.61	1865.32	1668.50	1436.59
Current Liabilities & Provisions	5351.76	4992.93	4684.44	3680.55	3077.77	3087.41	2771.09	2409.68	2385.36	1739.37
Sales	15763.80	14650.61	13561.78	12604.61	13375.27	12317.40	11523.93	10621.26	10312.12	9117.19
Cost of Materials	4574.03	4553.44	4204.59	4268.94	4051.96	3722.51	3890.29	3722.08	3166.44	2879.59
Staff Expenses	4626.10	4281.89	3774.07	3615.90	3608.24	3347.13	3087.13	2794.49	2428.82	2279.03
Contribution to Exchequer	2074.26	2038.06	1737.49	1455.00	1591.85	1378.26	1065.60	1033.49	1634.58	1403.67
Finance Cost	499.21	401.05	421.69	403.05	324.91	252.92	226.21	223.77	168.67	132.24
Profit/(Loss) Before Tax	489.90	411.30	321.87	(194.91)	566.88	657.04	589.33	473.04	382.94	287.00
Profit/(Loss) After Tax	362.02	172.93	307.04	(156.32)	388.87	472.11	351.44	317.77	254.80	274.63
Profit/(Loss) Retained	281.68	92.59	229.46	(156.32)	272.51	316.45	211.35	187.62	137.66	157.18
Dividend on Ordinary Shares	10%+	10%	10%	NIL	15%	30%	27%	25%	22.5%	17%

All figures are in lakhs ₹

+ Proposed

* Bonus Shares issued 1:2 capitalising from General Reserve.

Directors' Report

The Members

Your Directors have pleasure in presenting the 79th Annual Report on the business and operations of the Company together with Audited Statement of Accounts for the year ended March 31, 2016.

Financial Results:

The financial results for the year are as under :

<u>Particulars</u>	<u>2015-16</u>	<u>2014-15</u>
Profit Before Depreciation, Interest & Tax (PBDIT)	113270444	97568513
Interest / Finance Charges	49921240	40104674
Profit Before Depreciation and Tax (PBDT)	63349204	57463839
Depreciation / Amortization	14358909	16334235
Profit Before Tax (PBT)	48990295	41129604
Taxation Charge		
- Current Tax	13000000	10000000
Deferred Tax Charge / (Written Back)	(667614)	(2874650)
- Tax adjustment of earlier years	456178	16711535
Profit After Tax (PAT)	36201731	17292719
Balance available for appropriation	36201731	17292719
Appropriations		
Proposed Dividend	6674518	6674518
Corporate Dividend Tax	1359001	1359001
Transfer to General Reserve	28168212	9259200
Surplus carried to Balance Sheet		
Earnings per Ordinary share (₹)		
- Basic	5.42	2.59
- Diluted	5.42	2.59
Dividend per Ordinary Share (₹)	₹ 1.00	₹ 1.00

Dividend

Your Directors recommended a dividend @ 10% (Previous Year @ 10%.) of ₹ 1.00 per equity share for the year ended March 31, 2016 subject to the approval of the shareholders at the ensuing Annual General Meeting.

Year in Retrospect – Management discussion and analysis

During the year under review several of our products prices had to be reduced as per order of N.P.P.A. (National Pharmaceutical Pricing Authority). It is surprising where the inflation is in full swing, cost of living index is going up how NPPA has come up with a ruling to reduce the prices across the board. Both IDMA (Indian Drug Manufacturers' Association) and OPPI (Organization of Pharmaceutical Producers of India) have strongly objected to it. During the year NPPA widened its ambit. Several of our products, which were not covered by DPCO (Drug Price Control Order), came under the purview of DPCO. While DPCO'13 was promulgated with intention of reducing price control of drugs, the DPCO authorities seems to have other views. As a result we have incurred additional cost to add sticker to the goods lying in the Godown of ours and our wholesalers.

Pharmaceuticals sector is the third largest among the 25 odd sectors in terms of volume and 13th largest in terms of value. According to IBEF (Indian Brand Equity Foundation), Indian pharmaceutical sector accounts for about 2.4 per cent of the global pharmaceutical industry in value terms and 10 per cent in terms of volume. The branded generics segment dominates the pharmaceuticals sector, constituting nearly 70 to 80 per cent of the market.

Directors' Report

According to Associated Chambers of Commerce and Industry of India (ASSOCHAM), the pharmaceutical sector in India will register higher growth during the course of the next five years (22 per cent) as compared to a CAGR of about 14 per cent clocked by the sector during 2010-14.

During the year under review, we have introduced 7 new products in our list of products, they are - Pyrigesic A, Pyrigesic T, Calron-D, Locula TR (renamed), Zoamet-S, D3 Baby and D3 Baby Plus. Many more is on the go in near future.

Market Size

The Indian pharma industry, which is expected to grow over 15 per cent per annum between 2015 and 2020, will outperform the global pharma industry, which is set to grow at an annual rate of 5 per cent between the same periods. The market is expected to grow to US\$ 55 billion by 2020, thereby emerging as the sixth largest pharmaceutical markets globally by absolute size.

Roads Ahead

The Indian pharmaceutical market size is expected to grow to US\$ 100 billion by 2025, driven by increasing consumer spending, rapid urbanization and raising healthcare insurance among others.

Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers that are on the rise.

The Indian government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augur well for the pharmaceutical companies.

Current Year

As reported in last year's Report, sales were not up to the expectation due to increase in costs particularly employees' cost and reduction in price of some of our products the Profit Before Tax stood at ₹ 4.90 Crores (Previous year – ₹ 4.11 Crores) on a turnover of ₹ 157.64 Crores (Previous year – ₹ 146.51 Crores). The Board is strategizing to meet this Challenge.

Capital Expenditure

During the year, Company borrowed Rs. 6 crores from UBI for capital expenses. The funds will create new working area conforming with WHO GMP (World Health Organisation Good Manufacturing Practice) standard. The work is nearly completed and we hope to utilize the facility soon.

Industrial Relations

The relations remained cordial during the year. We are in the process of resolving some issues raised by our workmen in Durgapur with active intervention of the Govt. of West Bengal.

Transfer of Unclaimed Dividend to Investor Education and Protection Fund

Pursuant to Section 205 C of the Companies Act, 1956, (Section 124 of the Companies Act, 2013 yet to be notified) amounts lying unclaimed in the unpaid dividend accounts of the Company, is required to be transferred to the Investor Education and Protection Fund (IEPF) of the Central Government after such amount has remained unclaimed or unpaid for a period of seven years from the date of transfer to the unpaid dividend account.

During the year, the Company transferred an amount of ₹ 13,79,238/- to the IEPF being the unclaimed dividend for the financial period ended 31.03.2008.

Subsidiary Companies and Consolidated Financial Statements

As on 31st March, 2016, the Company has one wholly owned subsidiary "Qasar Healthcare Private Ltd."

The Consolidated Financial Statements of the Company and its subsidiary, prepared in accordance with relevant Accounting Standards specified in the Companies Act, 2013 read with the rules made there under, form part of the Annual Report. The necessary information as required to be given in terms of the first proviso of sub-section 3 of Section 129 of the Companies Act, 2013 is given in this Annual Report.

In terms of –

- (i) Clause (a) of fourth proviso to sub-section (1) of Section 136 of the Companies Act, 2013, a copy of the Balance Sheet, Statement of Profit and Loss and other documents of its subsidiary companies shall be placed on the website of the Company, viz. www.eastindiapharma.org.
- (ii) Clause (b) of fourth proviso to sub-section (1) of Section 136 of the Companies Act, 2013, the said documents/details shall be made available, upon request, to any member of the Company.

Directors' Report

Accreditation

The Company continues to enjoy ISO 9001–2008 certification by DET NORSKE VERITAS (DNV) and GMP – Schedule M (2001) compliance certificate from Directorate of Drugs Control, W.B.

Transfer to General Reserve

An amount of ₹ 28168212 is proposed to be transferred to the general reserve.

Public Deposits

The Company has neither accepted nor repaid any Public Deposit during the year. All the deposits earlier accepted have been fully repaid.

Material Changes and Commitments Affecting Financial Position

Between end of the Financial Year and Date of Report

There have been no material changes and commitments affecting financial position between end of the financial year and the date of the report.

Changes in Directors and Key Managerial Personnel

There has not been any change during the year.

Pursuant to Section 152 of the Companies Act, 2013 and in terms of the Articles of Association of the Company, Dr. Ranabir Mukherji (DIN 00042992) & Mr. Chiraranjan Addy (DIN 06606168), Directors of the Company, will retire by rotation at the ensuing Annual General Meeting and being eligible, offers themselves for re-appointment. Your Board has recommended their re-appointment. Brief profiles of Dr. Ranabir Mukherji & Mr. Chiraranjan Addy are mentioned in **Annexure** herein below.

During the year under review, pursuant to the provisions of Section 2(51) and Section 203 of the Companies Act, 2013 read with the rules made there under, the following existing officials of the Company were designated / classified as whole time Key Managerial Personnel of the Company -

1. Mr. Amit Kumar Sen & Mr. Debarshi Duttagupta both Managing Director;
2. Mr. Nirjhar Mukhopadhyay, Secretary & Chief Compliance Officer; and
3. Mr. Subrata Ray, Chief Financial Officer.

Number of Meetings of the Board of Directors

The Board of Directors of the Company met 4 (Four) times during the year 2015-16 i.e. on 30th June, 2015, 7th August, 2015, 27th November, 2015 & 3rd March, 2016.

The gap between two consecutive meetings did not exceed one hundred twenty days.

Sl. No.	NAME	No. of Board Meetings		Whether attended last AGM held on 16.09.2015
		attended during 2015-16		
		Held	Attended	
1.	Dr. Ranabir Mukherji	04	04	Yes
2.	Mr. Probir Roy	04	04	Yes
3.	Mr. Sukamal Chandra Basu	04	04	Yes
4.	Mr. Dilip Samadar	04	03	Yes
5.	Dr. Himadri Sengupta	04	04	Yes
6.	Prof. Suman Kumar Mukerjee	04	04	Yes
7.	Mr. Chiraranjan Addy	04	03	Yes
8.	Dr. Abhijit Banerjee	04	04	Yes
9.	Dr. Tapas Raychaudhury	04	03	Yes
10.	Mr. Amit Kumar Sen	04	04	Yes
11.	Mr. Debarshi Duttagupta	04	04	Yes

Directors' Report

Audit Committee

The composition, terms of reference etc. of the Audit Committee is provided below :

Members :

- | | |
|------------------------------|-----------------------|
| (a) Mr. Probir Roy, Chairman | Independent Directors |
| (b) Mr. Sukamal Chandra Basu | |
| (c) Mr. Dilip Samadar | |
| (d) Mr. Amit Kr. Sen | |
| (e) Mr. Debarshi Duttagupta | |

The Audit Committee is constituted in line with Section 177 of the Companies Act, 2013.

The Audit Committee comprises of three Independent, Non-Executive Directors namely Mr. Probir Roy (Chairman), Mr. Sukamal Chandra Basu and Mr. Dilip Samadar. The CFO, the Chief Accountant, the Internal Auditor, the Statutory Auditors and the Cost Auditors are permanent invitees to the meetings of the Audit Committee. The Company Secretary acts as the Secretary to the Audit Committee. The Committee reviews various aspects of internal controls and the Internal Auditors' Report.

The Audit Committee has met on 7th August, 2015 during the financial year 2015-16.

All the Directors except Mr. Dilip Samadar attended the meeting. Mr. Dilip Samadar was given leave of absence.

There have been no instances of non-acceptance of any recommendations of the Audit Committee by the Board during the financial year under review.

Independent Directors MeetingsMembers :

- (a) Mr. Probir Roy
- (b) Mr. Sukamal Chandra Basu
- (c) Mr. Dilip Samadar

The Independent Directors met on 19th February, 2015 to discuss the matters as envisaged in Schedule IV of the Companies Act, 2013.

All the Directors were present.

Vigil Mechanism / Whistle Blower Policy

The Company has established a Vigil Mechanism / Whistleblower Policy for the employees and others to report their genuine concerns or grievances and the same have been uploaded on the website of the Company at www.eastindiapharma.org.

The Audit Committee of the Company oversees the Vigil Mechanism.

Independent Directors' Declarations

In terms of provisions of the Section 149(7) of the Companies Act, 2013, all the Independent Directors of the Company have furnished a declaration to the Compliance Officer of the Company at the meeting of the Board of Directors held on 3rd March, 2016 stating that they fulfill the criteria of Independent Director as prescribed under section 149(6) of the Companies Act, 2013 and are not being disqualified to act as an Independent Director.

Directors' Responsibility Statement

As required by Section 134 (5) of the Companies Act, 2013, based on the information and representations received from the operating management, your Directors confirms that:

- (a) in the preparation of the annual accounts, the applicable accounting standards have been followed along with the proper explanation relating to material departures;
- (b) the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit & loss of the Company for that period;
- (c) the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) the Directors have prepared the annual accounts on a 'going concern' basis;
- (e) the Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively;

Directors' Report

- (f) the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Board Evaluation

The Performance evaluation of the Board, its committee and individual Directors was conducted and the same was based on questionnaire and feedback from all the Directors on the Board as a whole, its committees and self-evaluation.

The Chairperson of the Nomination and Remuneration Committee (NRC) held separate discussions with each of the Directors of the Company and obtained their feedback on overall Board effectiveness as well as on each of the other Directors.

Based on the questionnaire and feedback, the performance of every Director was evaluated by the NRC.

Some of the key criteria for performance evaluation, as laid down by the NRC were as follows-

Performance evaluation of Directors :

- 1 Contribution at Board/ Committee meetings
- 1 Guidance/ Support to Management outside Board / Committee Meetings

Performance evaluation of Board and Committees:

- 1 Board structure and composition
- 1 Degree of fulfillment of key responsibilities
- 1 Establishment and delineation of responsibilities to Committees
- 1 Effectiveness of Board processes, Information and Functioning
- 1 Board Culture and Dynamics
- 1 Quality of relationship between the Board and Management
- 1 Efficacy of communication with External Stakeholders
- 1 Committees- strengths and areas of improvement

Nomination and Remuneration Committee

The composition, key objectives etc. of the Nomination and Remuneration Committee is given below:

Members :

- (a) Mr. Probir Roy
- (b) Mr. Sukamal Chandra Basu
- (c) Prof. Suman Mukerjee

The Committee met on 4th August, 2015. Attended by all the members.

The Committee has formulated a Nomination and Remuneration Policy and the same has been uploaded on the website of the Company at www.eastindiapharma.org.

Stakeholders' Relationship Committee

Members :

- (a) Mr. Chiraranjan Addy, Chairman
- (b) Dr. Himadri Sengupta
- (c) Dr. Abhijit Banerjee

The Committee met 4 (Four) times on 30.06.2015, 07.08.2015, 27.11.2015 and 15.01.2016.

The Committee is empowered to consider and approve the physical transfer/transmission/transposition of shares, issue of new/duplicate share certificates. The Committee also specifically looks into the Redressal of shareholders' and investors' complaints/grievances pertaining to transfer of shares, non-receipt of dividend warrants etc.

So far the committee has received no complaints from any stakeholders.

Disclosure under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

In accordance with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made there under, the Company formulated an internal Policy on Sexual Harassment at Workplace (Prevention, Prohibition and Redressal) during the year under review.

Directors' Report

The policy aims at educating employees on conduct that constitutes sexual harassment, ways and means to prevent occurrence of any such incident, and the mechanism for dealing with such incident in the unlikely event of its occurrence. A five member Internal Complaints Committee (ICC) has been constituted in accordance with the Act.

The ICC is responsible for Redressal of complaints related to sexual harassment of women at the workplace in accordance with procedures, regulations and guidelines provided in the Policy.

During the year under review there were no complaints referred to the ICC.

Corporate Social Responsibility

The Company was not required to constitute a Corporate Social Responsibility Committee during the year under review.

Related Party Transactions

No related party transactions were entered into by the Company during the financial year ended March 31, 2016. Therefore, the provisions of Section 188 of the Companies Act, 2013 were not attracted.

Auditors And Auditors Report

The Auditors, M/s, APS Associates (Firm Registration No. 306015E) were re-appointed as the Statutory Auditors of the Company under Section 139 of the Companies Act, 2013 to hold office for a period of five years up to the conclusion of the 82nd Annual General Meeting in 2019. They are eligible for re-appointment for the financial year 2015-16. Your Board recommends ratification of their appointment as the Statutory Auditors at the ensuing Annual General Meeting for a period up to the conclusion of the 82nd Annual General Meeting of the Company.

Auditors' Report

The notes on account referred to in the Auditors' Report are self-explanatory and therefore, do not call for any further explanations or comments.

There are no qualifications, reservations or adverse remarks or disclaimer made in the Auditors' Report, which requires any clarification or explanation.

Cost Auditor

Pursuant to section 148 and other applicable provisions, if any, of the Companies Act, 2013 read with Companies (Audit and Auditors) Rules, 2014, the Board of Directors of your Company has appointed M/s DGM & Associates, Cost Accountants as the Cost Auditor for FY 2016-2017 for conducting the cost records of the Company on the recommendations made by the Audit Committee. The remuneration proposed to be paid to the cost auditor is subject to ratification by the members at ensuing Annual General Meeting.

Internal Control System

The Company has adequate internal control system commensurate with its size and business. The Internal Auditors review that all the transactions of the Company are in line with the compliance of laws, policies and procedures and have been correctly recorded and reported. The internal Audit is conducted on regular basis and the reports are submitted to the Audit Committee of Directors at their quarterly meetings.

Human Resources

As on 31st March, 2016, the Company had 1263 employees including 244 managerial personnel.

The Company has excellent combination of experienced and talented Technical Managers. The Company also undertakes on regular basis various training programmes to keep its employees updated on new technical developments and information, which directly results in optimum capacity utilization and cost effectiveness.

The Company's relation with its employees continues to be cordial. The Company always reciprocates commitments to its employees in order to motivate them to perform the best.

Statutory Compliances

All declarations and compliances with respect to the applicable statutes, enactments and guidelines are submitted at every meeting of the Board of Directors of the Company. The Company Secretary who is also the Compliance Officer gives a declaration of compliance to the Board with respect to the applicable provisions of Companies Act, 2013.

Particulars of Loans, Guarantees or Investments

During the period under review, the Company has not made any loan, guarantee or investment in terms of provisions of Section 186 of the Companies Act, 2013.

Particulars Of Employees

There are no employees whose particulars are required to be published under Section 197 of the Companies Act, 2013 and rules there under.

Directors' Report

Energy Conservation, Technology Absorption and Foreign Exchange Earnings and Outgo

The particulars relating to energy conservation, technology absorption, foreign exchange earnings and outgo, required to be disclosed by Section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 are provided in the **Annexure-I** to this Report.

Risk Management

A robust and integrated enterprise risk management framework is in existence under which the common prevailing risks in the Company are identified, the risks so identified are reviewed on periodic basis by the Audit Committee and the management's actions to mitigate the risk exposure in a timely manner are assessed.

A risk management policy under the above said enterprise risk management framework as approved by the Board has been adopted by the Company and being reviewed on yearly basis.

Extract of Annual Return

The details forming part of the extract of the Annual Return in Form MGT-9, as required under Section 92(3) of the Companies Act, 2013 read with Rule 12(1) of the Companies (Management and Administration) Rules, 2014 is attached as "**Annexure II**" to this Report.

Appreciation and Acknowledgement

Your Directors would like to express their appreciation for the assistance and co-operation received from the Government authorities, Banks, customers, business associates medical fraternity and members during the year under review. Your Directors also wish to place on record their deep sense of appreciation for the committed services by the executives, staff and workers of the Company.

for and on behalf of the Board of Directors

Place : Kolkata

Sd/- Dr. Ranabir Mukherji

Date : August 11, 2016

Chairman

Form No. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts / arrangements entered into by the Company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto.

1. Details of contracts or arrangements or transactions not at arm's length basis:

NIL (All related transactions are taken up on arms length basis).

2. Details of material contracts or arrangement or transactions at arm's length basis

a) Name(s) of the related party and nature of relationship	Qasar Healthcare Private Limited
b) Nature of contracts/arrangements/transactions	1. Sales Transactions of ₹ Nil 2. Advances of ₹ Nil 3. Receivable against sales of ₹ Nil
c) Duration of the contracts/arrangements/transactions	No Transactions had taken place during the period 1st. April, 2015 to 31st. March, 2016
d) Salient terms of the contracts or arrangements or transactions including the value, if any	-
e) Date(s) of approval by the Board, if any	-
f) Amount paid as advances, if any	Nil

For and on behalf of the Board of Directors

Place: Kolkata

Sd/-Dr. Ranabir Mukherji

Date: August 11, 2016

Chairman

ANNEXURE - I TO THE DIRECTORS' REPORT**Nomination and Remuneration Policy**

The objectives of this Policy include the following:

- 1 To lay down criteria for identifying persons who are qualified to become Directors;
- 1 To formulate criteria for determining qualification, positive attributes and independence of a Director;
- 1 To determine the composition and level of remuneration, including reward linked with the performance, which is reasonable and sufficient to attract, retain and motivate Directors and KMP, to work towards the long term growth and success of the Company;
- 1 To frame guidelines on the diversity of the Board;

Definitions :

Unless the context requires otherwise, the following terms shall have the following meanings:

“Director” means a Director of the Company.

“Key Managerial Personnel” or “KMP” means –

- (i) the Chief Executive Officer or the Managing Director;
- (ii) the Whole-time Director;
- (iii) the Chief Financial Officer;
- (iv) the Company Secretary; and
- (v) such other officer as may be prescribed under the applicable law.

Criteria for identifying persons who are qualified to be appointed as a Director of the Company:

Section 164 of the Companies Act, 2013 (“Act”) provides for the disqualifications for appointment of any person to become Director of any company. Any person who in the opinion of the Board of Directors (“Board”) is not disqualified to become a director, and in the opinion of the Board, possesses the ability, integrity and relevant expertise and experience, can be appointed as Director of the Company.

Independent Directors

For appointment of any person as an Independent Director he / she should possess qualifications as mentioned in Section 149 of the Companies Act, 2013 along with the Rules made thereunder.

Appointment criteria and qualifications

The Nomination & Remuneration Committee (“Committee”) shall identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director (including Independent Directors), or KMP and recommend to the Board his / her appointment.

Such person should possess adequate qualification, expertise and experience for the position he/she is considered for appointment. The Committee has discretion to decide whether qualification, expertise and experience possessed by a person is sufficient/satisfactory for the concerned position.

Evaluation

The Committee shall carry out evaluation of performance of every Director or KMP at regular interval and at least on a yearly basis.

Evaluation of Directors

In terms of Section 149 of the Act read with Schedule IV of the said Act the Independent Directors shall at its separate meeting review the performance of non-independent Directors based on the parameters that are considered relevant by the Independent Directors.

The Board as a whole shall evaluate the performance of Independent Directors. During such evaluation the Directors being evaluated shall be excluded from the meeting.

Evaluation of KMP and Senior Management Personnel

Criteria for evaluating performance of KMP (other than Directors) and Senior Management Personnel shall be as per the internal guidelines of the Company on performance management and development.

Directors' Report

Criteria for evaluation performance of Other Employees

The respective Departmental Chiefs of the Company shall evaluate the performance of Other Employees. In this regard, the Chiefs shall decide upon the criteria for evaluating performance of Other Employees.

Remuneration of Directors and KMP :

The remuneration /compensation/commission etc. to Managing Director / Whole-time Director and remuneration of KMP will be determined by the Committee and recommended to the Board for approval. Commission to other Directors (including Independent Directors) shall be subject to the approval of the shareholders of the Company and Central Government, wherever required.

Remuneration/commission to Directors (including Independent Directors) as per the statutory provisions of the Act and the rules made thereunder for the time being in force within limits approved by shareholders shall be decided by the Board.

Increments to the existing remuneration/compensation structure payable to Managing Director / Wholetime Directors and KMP may be recommended by the Committee to the Board which should be within the slabs if any, approved by the shareholders in the case of Directors.

Sitting Fees

Non-Executive Directors including Independent Directors may receive remuneration by way of fees for attending meetings of Board or its committee within limits prescribed by the Central Govt.

Remuneration to Senior Management Personnel

The Committee has delegated its powers under this Policy with respect to Senior Management Personnel (other than their appointment) and other employees two Managing Directors and they shall be entitled to take decisions with respect to remuneration of Senior Management Personnel and other employees / their extension after attainment of applicable retirement age / employee welfare measure including provision of loans (with or without interest as per statutory provisions) through wage settlements or company rules/regulations or otherwise.

REMUNERATION TO OTHER EMPLOYEES

The respective Chiefs of the departments of the Company with Managing Director's approval, will determine from time to time the remuneration payable to Other Employees. The powers of the Committee in this regard have been delegated to the Administrative Chief of the Company.

BOARD DIVERSITY

With a view to achieving a sustainable and balanced development, the Company sees increasing diversity at the Board level as an essential element in supporting the attainment of its strategic objectives and its sustainable development. The Company while appointing may consider the following criteria:

Appoint those persons who possess relevant experience, integrity, understanding, knowledge or other skill sets that may be considered by the Board as relevant in its absolute discretion, for the business of the Company etc.

The Board shall have the optimum combination of Directors, from different areas, fields, backgrounds and skill sets as may be deemed absolutely necessary.

The Board shall have members who have accounting or related financial management expertise and are financially literate.

**ANNEXURE –II TO THE DIRECTOR'S REPORT
PARTICULARS WITH RESPECT TO CONSERVATION OF ENERGY, ETC AS PER COMPANIES
(ACCOUNTS) RULES, 2014**

A. CONSERVATION OF ENERGY

	SARSUNA UNIT	DURGAPUR UNIT
i) The steps taken or impact on conservation of energy	A Capacitor Bank had been Installed in the FY 2014-2015 to enhance the power factor and there was a notable improvement in the year of installation. Further process is currently being undertaken for more efficient utilization of power. The current year power factor : 0.85	Power Factor had improved after a capacitor bank was installed in the FY 2014-2015. In the current year the power factor had remained almost the same i.e. 0.92.
ii) The steps taken by the Company for utilizing alternate source of Energy	NIL	NIL
iii) The capital investment on energy conservation equipment	NIL	NIL

B. TECHNOLOGY ABSORPTION

i) The efforts made towards technology absorption	Work on two analgesic, anti-inflammatory tablet Products are under development. A number of herbal products are also being developed. A few papers arising out of the work done in the R&D department, have been published in scientific journals.						
ii) The benefits derived like product improvement cost reduction, product development or import substitution	The R&D department worked on several existing products. A few of these have been reformulated to improve quality as well as to effect cost reduction. A few analytical methods, used for regular analysis of our products, were also improved.						
iii) In case of imported technology (imported during the last three year reckoned from the beginning of the financial year)	NIL						
iv) The expenditure incurred on Research and Development	<table border="0" style="margin-left: 20px;"> <tr> <td>Capital</td> <td>= ₹ NIL</td> </tr> <tr> <td>Recurring</td> <td>= ₹ 1,24,50,650</td> </tr> <tr> <td>Total</td> <td>= ₹ 1,24,50.650</td> </tr> </table>	Capital	= ₹ NIL	Recurring	= ₹ 1,24,50,650	Total	= ₹ 1,24,50.650
Capital	= ₹ NIL						
Recurring	= ₹ 1,24,50,650						
Total	= ₹ 1,24,50.650						
(Percentage of total turnover)	0.79%						

C. FOREIGN EXCHANGE EARNINGS AND OUTGO

i) The Foreign Exchange earned in terms of actual inflows during the year	₹ 7,14,229
ii) The Foreign Exchange outgo during the year in terms of actual outflows	₹ 1,020.28 Lakhs (including ₹ 1,020.09 Lakhs for import of Raw Materials)

Directors' Report

ANNEXURE - III TO THE DIRECTORS' REPORT

EXTRACT OF ANNUAL RETURN AS ON THE FINANCIAL YEAR ENDED ON 31st. MARCH, 2016.

[Pursuant to section 92(3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

i.	CIN	U24231WB1936PLC008598
ii.	Registration Date	27th. April, 1936
iii.	Name of the Company	East India Pharmaceutical Works Limited
iv.	Category / Sub-Category of the Company	Public Company limited by shares
v.	Address of the Registered office and contact details	6, Nandalal Bose Sarani, Kolkata 700071 Tel: +91 2287 3004 /07/09/3041/ 22830709 Tele Fax: 91-33-22873852/22874289 Email : eastindia@eastindiapharma.org
vi.	Whether listed company	No
vii.	Name, Address and Contact details of Registrar and Transfer Agent, if any	C B Management Services (P) Limited P-22, Bondel Road, Kolkata - 700 019

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10% or more of the total turnover of the company shall be stated:-

Sl. No.	Name and Description of main products / services	NIC Code of the Product / service	% to total turnover of the Company
1	Manufacture of bulk drugs, Manufacture & sale of formulations & Trading Activities	304, 304.1	100%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

Sl. No.	Name And Address of The Company	CIN/GLN	Holding/ Subsidiary/ Associate	% of shares held	Applicable Section
1.	Qasar Healthcare Private Limited 102, S.P. Mukherjee Road, 3rd. Floor, Kolkata 700026	U85110WB1993PTC58605	Subsidiary	99.5%	Section 2(87)

Directors' Report

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i. Category-wise Share Holding

Category of Shareholders	No. of Shares held on 1st. April, 2015				No. of Shares held on 31st. March, 2016				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoter									
1) Indian									
a) Individual/HUF	Nil	1817757	1817757	27.2343	Nil	1828974	1828974	27.4023	0.1680
b) Central Govt.	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
c) State Govt(s)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
d) Bodies Corp.	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
e) Banks / FI	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
f) Any Other	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Sub-total (A)(1):-	Nil	1817757	1817757	27.2343	Nil	1828974	1828974	27.4023	0.1680
2) Foreign									
a) NRIs-Individuals	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
b) Other-Individuals	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
c) Bodies Corp.	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
d) Banks / FI	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
e) Any Other	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Sub-total (A)(2):-	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Total Shareholding (A)=(A)(1)+(A)(2)	Nil	1817757	1817757	27.2343	Nil	1828974	1828974	27.4023	0.1680
B. Public Shareholding									
1. Institutions									
a) Mutual Funds	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
b) Banks / FI	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
c) Central Govt	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil

Directors' Report

d) State Govt(s)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
e) Venture Capital Funds	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
f) Insurance Companies	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
g) FII's	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
h) Foreign Venture Capital Funds	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
i) Others (specify)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Sub-total (B)(1)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
2. Non Institutions									
a) Bodies Corp.									
(i) Indian	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
(ii) Overseas	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
b) Individuals									
(i) Individual shareholders holding nominal share capital upto Rs. 1 lakh	Nil	2963649	2963649	44.4024	Nil	2940062	2940062	44.0491	(0.3533)
(ii) Individual shareholders holding nominal share capital in excess of Rs. 1 lakh	Nil	1861236	1861236	27.8857	Nil	1873308	1873308	28.0666	0.1809
c) Others (Specify)	Nil	31876	31876	0.4776	Nil	32174	32174	0.4820	0.0044
Sub-total (B)(2)	Nil	4856761	4856761	72.7657	Nil	4845544	4845544	72.5977	(0.1680)
Total Public Shareholding (B)=(B)(1)+(B)(2)	Nil	4856761	4856761	72.7657	Nil	4845544	4845544	72.5977	(0.1680)
C. Shares held by Custodian for GDRs & ADRs									
Grand Total (A+B+C)	Nil	6674518	6674518	100.00	Nil	6674518	6674518	100.00	0.00

Directors' Report

ii. Shareholding of Promoters

Sl. No.	Shareholder's Name	Number of shares held on April 1, 2015			Number of shares held on March 31st, 2016			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1.	Amit Kumar Sen	643918	9.6474	Nil	643918	9.6474	Nil	Nil
2.	Indrani Sen	337003	5.0491	Nil	337003	5.0491	Nil	Nil
3.	Debarshi Duttagupta	650019	9.7388	Nil	650019	9.7388	Nil	Nil
4.	Nabamita Duttagupta	186817	2.7990	Nil	198034	2.9670	Nil	0.1680
	Total	1817757	27.2343	Nil	1828974	27.4023	Nil	0.1680

iii. Change in Promoters' Shareholding (please specify, if there is no change)

Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
	No. of shares	% of total shares of the company	No. of shares	% of total shares of the company

At the beginning of the year

1. Amit Kumar Sen	643918	9.6474	643918	9.6474
2. Indrani Sen	337003	5.0491	337003	5.0491
3. Debarshi Duttagupta	650019	9.7388	650019	9.7388
4. Nabamita Duttagupta	186817	2.7990	198034	2.9670
Total	1817757	27.2343	1828974	27.4023

Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):

1. Nabamita Duttagupta (due to Transfer)	11217	0.1680	198034	2.9670
Total	11217	0.1680	198034	2.9670

At the End of the year, March 31, 2016

1. Amit Kumar Sen	643918	9.6474	643918	9.6474
2. Indrani Sen	337003	5.0491	337003	5.0491
3. Debarshi Duttagupta	650019	9.7388	650019	9.7388
4. Nabamita Duttagupta	198034	2.9670	198034	2.9670
Total	1828974	27.4023	1828974	27.4023

iv. Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs)

Top Ten Shareholders	Shareholding as on April 1, 2015		Shareholding as on March 31, 2016	
	No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
Gita Sen	112686	1.6883	112686	1.6883
Sanghamitra Duttagupta	109428	1.6395	109428	1.6395

Directors' Report

Atish Kumar Sen	109255	1.6369	109255	1.6369
Mahendra Girdharilal	80890	1.2119	80890	1.2119
Diptish Kanti Basu	67758	1.0152	67758	1.0152
Kalyan Sen	60750	0.9102	60750	0.9102
Ratnamala Ray	56740	0.8501	56740	0.8501
Tukaram Ganesh Kandalkar	42525	0.6371	42525	0.6371
Pranesh Raghunath Dhund	42525	0.6371	42525	0.6371
Indra Kumar Bagri	37402	0.5603	38915	0.5830

v. Shareholding of Directors and Key Managerial Personnel

For each of the Directors and KMP	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
	No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
At the Beginning of the year, April 1, 2015				
Subrata Ray	15126	0.2266	15126	0.2266
At the End of the year, March 31, 2016				
Subrata Ray	15126	0.2266	15126	0.2266

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	22,23,46,901	-	-	22,23,46,901
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	22,23,46,901	-	-	22,23,46,901
Change in Indebtedness during the financial year				
- Addition	5,38,38,830	-	-	5,38,38,830
- Reduction	-	-	-	-
Net Change	5,38,38,830	-	-	5,38,38,830
Indebtedness at the end of the financial year				
i) Principal Amount	27,61,85,731	-	-	27,61,85,731
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	27,61,85,731	-	-	27,61,85,731

Directors' Report

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager

Sl. No.	Particulars of Remuneration	Name of MD/WTD/ Manager		Total Amount (in ₹)
		Amit Kumar Sen	Debarshi Duttagupta	
1.	Gross salary			
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	40,00,000	25,25,000	65,25,000
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	3,34,406	6,70,287	10,04,693
	(c) Profits in lieu of salary u/s 17(3) Income- tax Act, 1961			
2.	Stock Option	Nil	Nil	Nil
3.	Sweat Equity	Nil	Nil	Nil
4.	Commission			
	- as % of profit	Nil	Nil	Nil
	- others, specify	Nil	Nil	Nil
5.	Others, please specify Company's contribution to PF	4,80,000	3,03,000	7,83,000
6.	Company's contribution to Superannuation	—	4,50,000	4,50,000
7.	Total (A)	48,14,406	39,48,287	87,62,693
	Ceiling as per the Act		10% of the net profits of the Company	

B. Remuneration to other Directors:

Sl. No.	Particulars of Remuneration	Name of Directors			Total Amount (in ₹)
		Prabir Roy	Sukamal Chandra Basu	Dilip Samadar	
1.	Independent Directors				
	·Fee for attending board committee meetings	20,000	20,000	15,000	55,000
	·Commission	—	—	—	—
	·Others, please specify	—	—	—	—
	Total (1)	20,000	20,000	15,000	55,000

Sl. No.	Particulars of Remuneration	Name of Directors						Total Amount (in ₹)
		Ranabir Mukherji	Suman Kr. Mukerjee	Himadri Sengupta	Chiraranjan Addy	Abhijit Banerjee	Tapas Raychaudhury	
2.	Other Non-Executive Directors							
	Fee for attending board committee meetings	20,000	20,000	20,000	15,000	20,000	15,000	1,10,000
	Commission	—	—	—	—	—	—	—
	Others, please specify	—	—	—	—	—	—	—
	Total (2)	20,000	20,000	20,000	15,000	20,000	15,000	1,10,000
	Total (B)=(1+2)							1,65,000
	Total Managerial Remuneration (A+B)							89,27,693
	Overall Ceiling as per the Act							11% of the net profits of the Company

Directors' Report

C. Remuneration to Key Managerial Personnel Other Than MD /Manager /WTD

Sl. No.	Particulars of Remuneration	Key Managerial Personnel			Total (in ₹)
		CEO	Company Secretary	CFO	
1.	Gross salary				
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	—	9,60,500	9,69,300	19,29,800
	(b) Value of perquisites u/s 17(2) of the Income-tax Act, 1961	—	53,400	64,200	1,17,600
	(c) Profits in lieu of salary u/s 17(3) of the Income-tax Act, 1961	—	—	—	—
2.	Stock Option	—	Nil	Nil	Nil
3.	Sweat Equity	—	Nil	Nil	Nil
4.	Commission				
	- as % of profit		Nil	Nil	Nil
	- others, specify	—	Nil	Nil	Nil
5.	Others, please specify PF& Superannuation Contribution	—	2,16,717	2,27,157	4,43,874
6.	Total	—	12,30,617	12,60,657	24,91,274

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the companies Act	Brief description	Details of Penalty/ Punishment/ Compounding fees imposed	Authority[RD /NCLT/Court]	Appeal made. If any (give details)
A. Company Penalty Punishment Compounding	}				
B. Directors Penalty Punishment Compounding			Not Applicable		
C. Other Officers In Default Penalty Punishment Compounding					

ANNEXURE - III TO THE DIRECTORS' REPORT

Brief Profile of Directors seeking re-appointment at the Annual General Meeting

Prof. (Dr.) Ranabir Mukherji

Date of Birth: 3rd. December, 1928

Qualification: MBBS (Cal) DOMS (Cal), MS (Lucknow), Ph. D (Cal), FRC Ophth. (London)

Resume: Prof. Mukherji is a leading Eye Surgeon of the country. He was the President of the All India Ophthalmological Society (Chennai-2000-2001), Former Vice Principal and Professor and Head of the Department of Ophthalmology, Calcutta National Medical College. Dr. Mukherji was a member of the Senate of the Calcutta University for many years. He is a Fellow of the State Medical Faculty of West Bengal and a member of its Governing Body. He is the Founder and Director of the Eye Care & Research Centre, Kolkata. Author of books on ophthalmology. Dr Mukherji has contributed about 70 scientific papers in different journals and in National and International conferences. He received the "Distinguished Service Award" of the Asia Pacific Academy of Ophthalmology for meritorious service in Ophthalmology in the Asia Pacific area in 1997.

Mr. Chiraranjan Addy

Date of Birth: 4th. September, 1937

Qualification: B.A., LLB., Attorney of Law

Resume: i) Enrolled as Solicitor & Advocate, Calcutta High Court and Supreme Court of India.
ii) Senior Partner M/s Sandersons & Morgans, Calcutta and Sandersons Morgans & Co., Bhubaneswar.
iii) Past President Rotary Club of Jodhpur Garden and presently member – Rotary Club of South Calcutta.
iv) Past Master Lodge Stanley No.78.
v) Past Supreme Ruler, Empress of India.

Independent Auditors' Report

To The Members of **EAST INDIA PHARMACEUTICAL WORKS LIMITED**

Report on the Standalone Financial Statements

We have audited the accompanying standalone financial statements of **East India Pharmaceutical Works Limited** ("the Company"), which comprise the Balance Sheet as at 31st March, 2016, the Statement of Profit and Loss, the Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that are operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31st March, 2016 and its profit and its cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report that :
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

Auditors' Report

- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of written representations received from the directors as on 31st March, 2016 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2016, from being appointed as a director in terms of Section 164(2) of the Act.
 - f) We give in the Annexure a report on the internal financial control in the Company.
 - g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us :
 - (i) The Company does not have any pending litigations which would impact its financial position.
 - (ii) The Company did not have any long-term contract including derivative contracts for which there were any material foreseeable losses.
 - (iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
2. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Government of India, Ministry of Corporate Affairs, in terms of sub-section (11) of Section 143 of the Act, we give in the Annexure a statement on the matters specified in paragraphs 3 and 4 of the Order.

Kolkata,
Dated, the 11th August, 2016

For APS ASSOCIATES
CHARTERED ACCOUNTANTS
(Registration No. 306015E)
(A.Dutta)
Partner
Membership No.017693

Auditors' Report

Annexure to the Independent Auditors' Report of even date on the Standalone Financial Statements of East India Pharmaceutical Works Limited

Statement under Companies (Auditor's Report) Order, 2016

1. a) The Company is maintaining proper records showing full particulars including quantitative details and situation of its fixed assets.
 - b) The fixed assets are physically verified by the management at reasonable intervals ; no material discrepancies were noticed on such verification.
 - c) The title deeds of immovable properties, other than self constructed buildings, are held in the name of the Company.
2. During the year, inventories were physically verified by the management at reasonable intervals. The discrepancies noticed on physical verification of inventories were not material and have been properly dealt with in the books of account.
3. According to the information and explanations given to us and as certified by the management, the Company has not granted any loan, secured or unsecured to companies, firms, limited liability partnerships or other parties covered in the register maintained under Section 189 of the Act.
4. According to the information and explanations given to us and as certified by the management, the Company has not granted any loans or made any investment or provided any guarantee or security as per provisions of Sections 185 and 186 of the Act.
5. The Company has not accepted any deposits within the meaning of Section 73 to 76 of the Act and the rules framed there under.
6. Pursuant to the rules made by the Central Government of India, the Company is required to maintain cost records as prescribed under Section 148 (1) of the Act in respect of its products. We are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. However, we have not made a detailed examination of such records with a view to determine whether they are accurate or complete.
7. a) According to the records of Company, undisputed statutory dues including provident fund, employees state insurance, income tax, sales tax, service tax, customs duty, excise duty and value added tax have generally been regularly deposited with the appropriate authorities.
 - b) According to the information and explanations given to us, following are the particulars of disputed dues on account of income tax, excise duty, service tax and sales tax matters which have not been deposited by the Company :

Auditors' Report

Name of the Statute	Nature of Demand	Amount (₹)	Relevant Period	Forum where dispute is pending	
Income Tax Act, 1961	Income Tax	43,17,790	2011-2012 and 2012-2013	Commissioner of Income Tax (Appeals) - XII, Kolkata	
Central Excise Act, 1944	Cenvat Credit & Education Cess	1,27,500	2007-2008	Assistant Comm. of Central Excise, Kolkata - V	
Central Excise Act, 1944	Central Excise Duty	2,61,23,380	2000-2001 to 2004-2005	Calcutta High Court	
Central Excise Act, 1944	Penalty	2,61,23,380	2000-2001 to 2004-2005		
Central Excise Act, 1944	Interest	93,56,536	2000-2001 to 2015-2016		
Central Excise Act, 1944	Interest	23,508	2008-2009 to 2012-2013		Commissioner, (Appeal - III A), Central Excise, Kolkata
Central Excise Act, 1944	Penalty	54,539	2008-2009 to 2012-2013		
Central Excise Act, 1944	Service Tax & Penalty	22,394	2009-2010 to 2011-2012		
Tamil Nadu General Sales Tax Act	Penalty	2,45,205	2005-2006 and 2006-2007		Appellate Deputy Commissioner (CT), Chennai
U.P. Trade Tax Act	Central Sales Tax	58,728	2005-2006	Additional Commissioner, Grade - II (Appeals)	
U.P. Trade Tax Act	U.P. Trade Tax	1,00,964	2005-2006		
U.P. Trade Tax Act	U.P. Trade Tax	38,340	2006-2007		
U.P. Trade Tax Act	Central Sales Tax	70,272	2006-2007		

8. According to the records of the Company and the information and explanations given to us, the Company has not defaulted in repayment of dues to its bankers.
9. During the year the Company has not raised any money through public offer. The term loans received during the year were applied for the purposes for which those were obtained.
10. According to the information and explanations given to us and as certified by the management no fraud on or by the Company was reported during the year.
11. Managerial Remuneration has been paid / provided in accordance with the provisions of Section 197 read with Schedule V of the Act.

Auditors' Report

12. The Company is not a Nidhi Company.
13. According to the information and explanations given to us all transactions with the related parties are in compliance with Section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the financial statements etc., as required by the applicable accounting standards.
14. The Company has not made any preferential allotment or private placement of securities during the year.
15. The Company has not entered into any non-cash transaction with its directors or persons related to any of them.
16. The Company is not required to be registered under Section 45 – IA of the Reserve Bank of India Act, 1934.

For APS ASSOCIATES
CHARTERED ACCOUNTANTS
(Registration No. 306015E)
(A.Dutta)

Kolkata,
Dated, the 11th August, 2016

Partner
Membership No.017693

Annexure to the Independent Auditors' Report of even date on the Standalone Financial Statements of East India Pharmaceutical Works Limited

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **East India Pharmaceutical Works Limited** ("the Company") as of March 31, 2016 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

Auditors' Report

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2016, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India.

Kolkata,
Dated, the 11th August, 2016

For APS ASSOCIATES
CHARTERED ACCOUNTANTS
(Registration No. 306015E)
(A.Dutta)
Partner
Membership No.017693

Balance Sheet

AS AT 31ST MARCH, 2016

	Note No.	31st March, 2016 ₹	31st March, 2015 ₹
I. EQUITY AND LIABILITIES			
(1) Shareholders' Funds			
(a) Share Capital	2	6,67,45,179	6,67,45,179
(b) Reserves and Surplus	3	33,95,23,059	31,13,54,847
(2) Non-current Liabilities			
(a) Long-Term Borrowings	4	1,80,13,635	NIL
(b) Long-Term Provision	8A	4,56,61,000	4,46,40,000
(3) Current Liabilities			
(a) Short-Term Borrowings	5	24,53,53,648	22,06,52,850
(b) Trade Payables	6	27,50,20,562	26,59,32,902
(c) Other Current Liabilities	7	20,61,27,212	17,14,47,489
(d) Short-Term Provisions	8B	2,15,09,434	1,89,66,319
TOTAL		121,79,53,729	109,97,39,586
II. ASSETS			
(1) Non-Current Assets			
(a) Fixed Assets			
(i) Tangible Assets	9	9,55,26,338	10,11,39,467
(ii) Intangible Assets	9	22,87,616	32,50,532
(iii) Capital work-in-progress		6,27,11,030	44,22,129
(b) Non-Current investments	10	99,500	99,500
(c) Deferred Tax Assets (net)	11	3,14,98,725	3,08,31,111
(d) Long-Term Loans and Advances	12	1,80,06,774	62,33,280
(2) Current Assets			
(a) Inventories	13	21,77,03,120	21,27,84,469
(b) Trade Receivables	14	58,43,73,826	56,16,88,287
(c) Cash and Cash Equivalents	15	15,27,51,766	12,69,60,162
(d) Short-Term Loans and Advances	16	5,09,95,034	5,03,30,649
(e) Other Current Assets	17	20,00,000	20,00,000
TOTAL		121,79,53,729	109,97,39,586
Significant Accounting Policies	1		

The accompanying notes numbered 1 – 38 form an integral part of the financial statements.

This is the Balance Sheet referred to in our report of even date.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693
Kolkata, Dated, the 11th. August, 2016

Sd/- R. Mukherji, P. Roy, C. Addy,
S. C. Basu, S. K. Mukerjee,
Directors A. Banerjee, T. Raychaudhury
Managing Directors A. K. Sen, D. Duttagupta
Secretary & CCO N. Mukhopadhyay
Chief Financial Officer S. Ray
Kolkata, Dated, the 11th. August, 2016

Statement of Profit and Loss

FOR THE YEAR ENDED 31ST MARCH, 2016

	Note No.	31st March, 2016		31st March, 2015	
		₹	₹	₹	₹
I. REVENUE FROM OPERATIONS					
Revenue from Sales	18	157,63,80,054		146,50,60,922	
Less : Excise Duty		(9,19,36,450)	1,48,44,43,604	(9,16,24,141)	1,37,34,36,781
Other Operating Revenues	18		28,43,892		40,65,401
II. OTHER INCOME	19		8,62,316		87,20,831
III. TOTAL REVENUE (I + II)			148,81,49,812		138,62,23,013
IV. EXPENSES :					
Cost of materials consumed	20		44,99,08,847		45,12,79,443
Purchases of Traded Goods			74,93,699		40,64,883
Changes in inventories of finished goods, work-in-progress and Traded Goods	21		(16,83,725)		(1,52,22,645)
Employee benefits expenses	23		46,26,09,928		42,81,89,430
Finance Costs	24		4,99,21,240		4,01,04,674
Depreciation and amortization Expenses			1,43,58,909		1,63,34,235
Research and Development expenses	25		1,24,50,650		1,19,97,506
Other expenses	26		44,40,99,969		40,83,45,883
Total Expenses			143,91,59,517		134,50,93,409
V. PROFIT BEFORE TAX (III – IV)			4,89,90,295		4,11,29,604
VI. TAX EXPENSE :					
(1) Current tax		1,30,00,000		1,00,00,000	
(2) Deferred tax		(6,67,614)		(28,74,650)	
(3) Tax Adj. of earlier Years		4,56,178	1,27,88,564	1,67,11,535	2,38,36,885
VII. PROFIT FOR THE YEAR (V-VI)			3,62,01,731		1,72,92,719
VIII. EARNINGS PER EQUITY SHARE :	27				
(1) Basic			5.42		2.59
(2) Diluted			5.42		2.59

The accompanying notes numbered 1 – 38 form an integral part of the financial statements.

This is the Statement of Profit and Loss referred to in our report of even date.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693
Kolkata, Dated, the 11th. August, 2016

Sd/- R. Mukherji, P. Roy, C. Addy,
S. C. Basu, S. K. Mukerjee,
Directors
A. Banerjee, T. Raychaudhury
Managing Directors
A. K. Sen, D. Duttagupta
Secretary & CCO
N. Mukhopadhyay
Chief Financial Officer
S. Ray
Kolkata, Dated, the 11th. August, 2016

Cash Flow Statement

FOR THE YEAR ENDED 31ST MARCH, 2016

	31st March,2016 ₹	31st March,2015 ₹
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax & extraordinary items	4,89,90,295	4,11,29,604
Adjustments For :		
Depreciation / Amortisation	1,43,58,909	1,63,34,235
(Profit)/ Loss on sale of Fixed Assets	(1,66,375)	993
Interest Received	(6,53,338)	(86,94,037)
Interest Paid	4,99,21,240	4,01,04,674
Operating Profit before working capital changes	11,24,50,731	8,88,75,469
(Increase)/Decrease in Inventories	(49,18,651)	(2,64,00,870)
(Increase)/Decrease in Trade & Other Receivables	(3,51,23,418)	(20,07,449)
Increase/ (Decrease) in Trade Payables	3,29,02,986	2,80,06,117
Cash generated from operations	10,53,11,648	8,84,73,267
Direct Tax paid	(1,01,52,063)	(2,41,48,622)
Net Cash Flow from Operating Activities	9,51,59,585	6,43,24,645
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(6,69,22,390)	(88,32,669)
Sale of Fixed Assets	10,17,000	22,000
Net Cash Flow from Investing Activities	(6,59,05,390)	(88,10,669)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from/(Repayment of) borrowings(net)	5,38,38,830	(23,67,004)
Payment of Dividend and Dividend Tax	(80,33,519)	(77,57,325)
Interest Paid	(4,99,21,240)	(4,01,04,674)
Interest Received	6,53,338	86,94,037
Net Cash Flow from Financing Activities	(34,62,591)	(4,15,34,966)
Net Cash Inflow (A+B+C)	2,57,91,604	1,39,79,010
Cash & Cash Equivalents- Opening	12,69,60,162	11,29,81,152
Cash & Cash Equivalents- Closing	15,27,51,766	12,69,60,162
	2,57,91,604	1,39,79,010

The accompanying notes numbered 1 – 38 form an integral part of the financial statements.

This is the Cash Flow Statement referred to in our report of even date.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693
Kolkata, Dated, the 11th. August, 2016

Sd/- R. Mukherji, P. Roy, C. Addy,
S. C. Basu, S. K. Mukerjee,
Directors A. Banerjee, T. Raychaudhury
Managing Directors A. K. Sen, D. Duttagupta
Secretary & CCO N. Mukhopadhyay
Chief Financial Officer S. Ray
Kolkata, Dated, the 11th. August, 2016

Notes forming part of Balance Sheet as at 31st March, 2016 and Statement of Profit and Loss for the year ended on 31st March, 2016

Note No.

1. Significant Accounting Policies

- (i) **Basis of Accounting :**
The accounts have been prepared on the principles of historical costs and going concern basis.
- (ii) **Revenue Recognition :**
All revenues are generally recognised on accrual basis. Gross sales is stated inclusive of Excise Duty, Sales Tax and VAT.
- (iii) **Fixed Assets :**
Fixed assets, including those utilised in R&D activities, are capitalised at cost of acquisition which includes freight, duties and taxes and incidental expenses and borrowing cost.
- (iv) **Borrowing Costs :**
Borrowing costs are recognised as expense in the period in which they are incurred, except those directly attributable to the acquisition and construction of qualifying assets.
- (v) **Depreciation :**
Depreciation is provided on the Written Down Value based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013.
- (vi) **Research and Development Expenses :**
Revenue expenditure on Research and Development is charged to revenue in the year in which it is incurred. Expenses of capital nature are capitalised.
- (vii) **Inventories :**
Inventories are valued at lower of Cost and Net Realisable Value. Cost is determined as follows :
- | | |
|---------------------------------------|---|
| (a) Raw Materials | : Weighted average basis |
| (b) Work-in-Progress | : Weighted average basis |
| (c) Finished Goods | : Cost of input plus appropriate overhead |
| (d) Traded Goods | : Cost |
| (e) Packing materials and consumables | : Weighted average basis |
- (viii) **Employee Benefits :**
Liabilities in respect of retirement benefits to employees are provided for as follows :
- (I) **Defined Benefit Plans :**
- Leave encashment benefits are provided for on the basis of Actuarial Valuation.
 - Superannuation Fund and Gratuity Fund on the basis of premium paid to the Life Insurance Corporation of India.
- (II) **Defined Contribution Plans :**
Provident / Pension Fund and ESI on the basis of actual liability accrued and paid to Government authorities.
- (ix) **Foreign Currency Transaction :**
Transaction in foreign currencies are accounted for at exchange rates prevailing on the date of transaction. Gain / Loss arising on account of rise or fall in overseas currencies vis-a-vis reporting currency between the date of transaction and that of payment is charged to revenue.
- (x) **Taxes on Income :**
Current Tax is determined as per the provisions of Income Tax Act, 1961. Deferred Tax liabilities/assets are recognised, subject to the consideration of prudence, on timing difference, being the difference between taxable income and accounting income.

Notes forming part of Balance Sheet as at 31st March, 2016 and
Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016		31st March, 2015	
	₹	₹	₹	₹
2. SHARE CAPITAL				
(a) Authorised :				
1,00,00,000 Ordinary Shares		10,00,00,000		10,00,00,000
(b) Issued :				
66,75,543 Ordinary Shares		6,67,55,430		6,67,55,430
Subscribed and paid up :				
66,74,858 Ordinary Shares fully called up		6,67,48,580		6,67,48,580
Less : Calls Unpaid		3,401		3,401
		6,67,45,179		6,67,45,179
(c) Par value per share		10.00		10.00
(d) Quantitative Reconciliation :				
Opening Balance as on 01.04.2015		66,74,518		66,74,518
Add : Shares issued during the year		NIL		NIL
Closing Balance as on 31.03.2016		66,74,518		66,74,518
(e) Shares held by each shareholder holding more than 5 percent shares specifying the number of shares held :				
<u>Name of the shareholder</u>		No. of shares		No. of shares
n Shri Amit Kumar Sen		6,43,918		6,43,918
n Shri Debarshi Dutttagupta		6,50,019		6,50,019
(f) Aggregate number of shares allotted as fully paid-up bonus shares during the period of five years immediately preceding the date as at which the Balance Sheet is prepared		22,24,778		22,24,778
(g) Calls unpaid		3,401		3,401
1 Calls unpaid by Directors and Officers		NIL		NIL
3. RESERVES AND SURPLUS				
(a) General Reserve:				
Opening Balance	30,33,44,847		29,00,48,732	
Add: Adjustment for Depreciation (Refer Note No. 37)	NIL		40,36,915	
	30,33,44,847		29,40,85,647	
Add : Profit after tax for the year	3,62,01,731		1,72,92,719	
	33,95,46,578		31,13,78,366	
Less : Provision for Dividend @ 10% (PY 10%)	66,74,518		66,74,518	
Provision for Dividend Distribution Tax	13,59,001	33,15,13,059	13,59,001	30,33,44,847
(b) Other Reserves:				
(i) Investment Fluctuation Reserve		10,000		10,000
(ii) Contingency Reserve		80,00,000		80,00,000
		33,95,23,059		31,13,54,847

Notes forming part of Balance Sheet as at 31st March, 2016 and Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016 ₹	31st March, 2015 ₹
4. LONG – TERM BORROWINGS		
Unsecured		
n Term Loan from United Bank of India (Repayable in quarterly instalments and secured by hypothecation of specific assets procured under loan)	1,68,82,880	NIL
n Car Loan from HDFC Bank Ltd. (Repayable in equated monthly instalments and secured against hypothecation of Vehicles)	11,30,755	NIL
	<u>1,80,13,635</u>	<u>NIL</u>
5. SHORT – TERM BORROWINGS		
Secured		
n From banks - n Cash Credit :		
l From United Bank of India	24,53,53,648	22,06,52,850
Nature of Security :		
Secured by hypothecation of entire current assets of the Company with additional collaterals of charge over immovable properties.	<u>24,53,53,648</u>	<u>22,06,52,850</u>
6. TRADE PAYABLES		
Sundry Creditors	27,50,20,562	26,59,32,902
	<u>27,50,20,562</u>	<u>26,59,32,902</u>

Notes forming part of Balance Sheet as at 31st March, 2016 and
Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016 ₹	31st March, 2015 ₹
7. OTHER CURRENT LIABILITIES		
(a) Current maturities of long-term Borrowings :		
n From banks -		
1 From United Bank of India (Repayable in Quarterly instalments and secured by hypothecation of specific assets procured under loan)	1,20,00,000	16,94,051
1 From HDFC Bank Ltd. (Repayable in equated monthly instalment and secured against hypothecation of Vehicles)	8,18,448	NIL
(b) Interest accrued and due on borrowings	3,24,107	7,74,275
(c) Unclaimed dividends*	95,79,359	1,10,25,770
(d) Other payables (Includes Statutory Dues)	18,34,05,298	15,79,53,393
	<u>20,61,27,212</u>	<u>17,14,47,489</u>

* There are no amounts due and outstanding to be credited to Investor Education and Protection Fund.

8. PROVISIONS

A. Long Term Provision -

Provision for Leave Encashment	4,56,61,000	4,46,40,000
--------------------------------	-------------	-------------

B. Short Term Provision -

(a) Provision for Leave Encashment	42,03,000	49,64,000
(b) Provision for Income Tax (Net of Advance Tax of ₹ 37,27,085 Previous Year ₹ 40,31,200)	92,72,915	59,68,800
(c) Provision for Proposed Dividend	66,74,518	66,74,518
(d) Provision for Tax on Proposed Dividend	13,59,001	13,59,001
	<u>2,15,09,434</u>	<u>1,89,66,319</u>

Notes forming part of Balance Sheet as at 31st March, 2016 and Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No. 9. FIXED ASSETS
Reconciliation of Gross and Net Carrying Amount of Each Class of Assets

Sl No	Particulars	Cost as on	Additions	Deletions	Cost as on	Depreciation / Amortisation			Net Value		
		March 31, 2015 ₹	during the year ₹	₹	March 31, 2016 ₹	Upto March 31, 2015 ₹	For the year 2015-2016 ₹	Deletions 2015-2016 ₹	Adjustment 2015-2016 ₹	Upto March 31, 2016 ₹	as on March 31, 2016 ₹
TANGIBLE ASSETS											
(a)	Land	7,82,047	-	-	7,82,047	-	-	-	-	-	7,82,047
(b)	Buildings	8,83,40,694	-	-	8,83,40,694	4,65,76,298	25,30,476	-	-	4,91,06,774	3,92,33,920
(c)	Plant and Equipment*	28,69,21,465	40,68,781	-	29,09,90,246	23,89,46,968	67,09,668	-	-	24,56,56,636	4,53,33,610
(d)	Computer	64,05,296	4,53,227	-	68,58,523	58,46,258	3,50,536	-	-	61,96,794	6,61,729
(e)	Furniture and Fixture	2,29,29,407	6,81,304	-	2,36,10,711	1,90,64,489	10,22,236	-	-	2,00,86,725	35,23,986
(f)	Vehicles	1,70,14,514	30,14,063	43,64,528	1,56,64,049	1,32,30,331	18,03,474	35,13,901	-	1,15,19,904	41,44,145
(g)	Office Equipment	1,78,00,856	4,16,116	-	1,82,16,972	1,53,90,468	9,79,603	-	-	1,63,70,071	18,46,901
Total		44,01,94,279	86,33,491	43,64,528	44,44,63,242	33,90,54,812	1,33,95,993	35,13,901	-	34,89,36,904	9,55,26,338
INTANGIBLE ASSETS											
	Copyrights, patents and other intellectual property rights, services and operating rights	1,56,47,278	-	-	1,56,47,278	1,23,96,746	9,62,916	-	-	1,33,59,662	22,87,616
Total		1,56,47,278	-	-	1,56,47,278	1,23,96,746	9,62,916	-	-	1,33,59,662	22,87,616

*Includes additions to Research and Development assets : ₹ NIL (₹ 3,24,613)



Notes forming part of Balance Sheet as at 31st March, 2016 and
Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No. 9. FIXED ASSETS (Contd.)

Sl No	Particulars	Cost as on	Additions	Deletions		Cost as on	Depreciation / Amortisation		Adjustment	Upto		Net Value as on March 31, 2015 ₹
		March 31, 2014 ₹	during the year ₹	₹	₹	March 31, 2015 ₹	For the year 2014-2015 ₹	March 31, 2014 ₹	2014-2015 ₹	March 31, 2015 ₹	March 31, 2015 ₹	
TANGIBLE ASSETS												
(a)	Land	7,82,047	-	-	-	7,82,047	-	-	-	-	-	7,82,047
(b)	Buildings	8,69,11,150	14,29,544	-	-	8,83,40,694	27,03,880	4,46,63,823	7,91,405	4,65,76,298	4,65,76,298	4,17,64,396
(c)	Plant and Equipment*	28,33,33,039	35,88,426	-	-	28,69,21,465	77,44,828	23,62,48,950	50,46,810	23,89,46,968	23,89,46,968	4,79,74,497
(d)	Computer	61,09,661	2,95,635	-	-	64,05,296	4,18,643	53,79,000	-48,615	58,46,258	58,46,258	5,59,038
(e)	Furniture and Fixture	2,25,34,012	3,95,395	-	-	2,29,29,407	14,08,919	1,78,24,910	1,69,340	1,90,64,489	1,90,64,489	38,64,918
(f)	Vehicles	1,73,23,366	3,24,436	6,33,288	-	1,70,14,514	17,70,346	1,21,06,453	36,173	1,32,30,331	1,32,30,331	37,84,183
(g)	Office Equipment	1,74,72,969	3,27,887	-	-	1,78,00,856	9,15,922	1,44,47,046	(27,500)	1,53,90,468	1,53,90,468	24,10,388
	Total	43,44,66,244	63,61,323	6,33,288	-	44,01,94,279	1,49,62,537	33,06,70,182	59,67,613	33,90,54,812	33,90,54,812	10,11,39,467
INTANGIBLE ASSETS												
	Copyrights, patents and other intellectual property rights, services and operating rights	1,56,47,278	-	-	-	1,56,47,278	13,71,698	1,10,25,048	-	1,23,96,746	1,23,96,746	32,50,532
	Total	1,56,47,278	-	-	-	1,56,47,278	13,71,698	1,10,25,048	-	1,23,96,746	1,23,96,746	32,50,532

*Includes additions to Research and Development assets : ₹ 3,24,613 (₹ NIL)

1. Adjustment made consequent to revision of useful lives pursuant to Schedule II to the Companies Act, 2013. (Please refer Note 37)
2. Certain tangible assets have been regrouped, wherever possible, in line with Schedule II to the Companies Act, 2013.

Notes forming part of Balance Sheet as at 31st March, 2016 and Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016 ₹	31st March, 2015 ₹
10. NON-CURRENT INVESTMENTS		
Investment in Equity Instruments -		
n 9,950 Equity Shares of Rs. 10 each fully paid up – Qasar Healthcare Pvt. Ltd. (Subsidiary Company – unquoted)	99,500	99,500
	<u>99,500</u>	<u>99,500</u>
11. DEFERRED TAX ASSETS (NET)		
Deferred Tax Liabilities :		
Depreciation as per Income Tax Act, 1961	6,42,96,936	6,00,70,939
Depreciation adjusted against Reserves and Surplus	19,30,697	19,30,697
Privilege Leave paid during the year	88,18,100	76,58,418
Research & Development Assets	1,02,98,155	1,02,98,155
Total (A)	<u>8,53,43,888</u>	<u>7,99,58,209</u>
Deferred Tax Assets :		
Depreciation charged in Accounts	9,09,91,432	8,62,38,633
Provision for Doubtful Debts	4,56,964	4,02,212
Provision for Leave Encashment for the year	2,53,94,217	2,41,48,475
Total (B)	<u>11,68,42,613</u>	<u>11,07,89,320</u>
Deferred Tax Asset (net) (B-A)	<u>3,14,98,725</u>	<u>3,08,31,111</u>
12. LONG – TERM LOANS AND ADVANCES (Unsecured, Considered Good)		
(a) Capital Advances	1,30,53,681	17,05,000
(b) Security Deposits	49,53,093	45,28,280
	<u>1,80,06,774</u>	<u>62,33,280</u>
13. INVENTORIES (At Lower of Cost and Net Realisable Value)		
(a) Raw materials	3,01,22,519	3,31,20,906
(b) Work-in-progress	79,12,387	1,18,166
(c) Finished Goods	14,38,80,469	15,13,72,131
(d) Traded Goods	22,34,947	8,53,781
(e) Packing materials and consumables	3,35,52,798	2,73,19,485
	<u>21,77,03,120</u>	<u>21,27,84,469</u>
The above includes goods in transit as under :		
(a) Raw materials	33,77,900	22,76,608
(b) Finished Goods	1,23,774	54,33,640
	<u>35,01,674</u>	<u>77,10,248</u>

Notes forming part of Balance Sheet as at 31st March, 2016 and
Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	₹	31st March, 2016 ₹	₹	31st March, 2015 ₹
14. TRADE RECEIVABLES				
(i) Debts outstanding for a period exceeding six months :				
Unsecured, considered good		4,66,08,239		5,75,22,022
Unsecured, considered doubtful	56,88,362		55,22,949	
Less : Provision	<u>56,88,362</u>	NIL	<u>55,22,949</u>	NIL
(ii) Other Debts :				
Unsecured, considered good		53,77,65,587		50,41,66,265
		<u>58,43,73,826</u>		<u>56,16,88,287</u>
15. CASH AND CASH EQUIVALENTS				
(a) Cash and Cash Equivalents :				
n Cash in Hand		6,27,497		5,38,153
n Balances with Banks - In Current Accounts		14,25,44,910		11,33,14,930
(b) Other Bank Balances :				
n In Unclaimed Dividend Accounts		95,79,359		1,10,25,770
n In Fixed Deposit Accounts		NIL		20,81,309
		<u>15,27,51,766</u>		<u>12,69,60,162</u>
16. SHORT – TERM LOANS & ADVANCES (Unsecured, Considered Good)				
(a) Security Deposits		41,47,431		37,57,331
(b) Other advances		4,68,47,603		4,65,73,318
		<u>5,09,95,034</u>		<u>5,03,30,649</u>
17. OTHER CURRENT ASSETS Unsecured Considered Good				
Realisable from EPFO		20,00,000		20,00,000
		<u>20,00,000</u>		<u>20,00,000</u>
18. REVENUE FROM OPERATIONS				
(a) Revenue from Sales	157,63,80,054		146,50,60,922	
Less : Excise Duty	<u>(9,19,36,450)</u>	148,44,43,604	<u>(9,16,24,141)</u>	137,34,36,781
(b) Other operating revenues :				
n Claim	7,15,500		1,93,093	
n Refund of Excise Duty	NIL		39,706	
n Liabilities no longer required written back	NIL		15,79,278	
n Others	<u>21,28,392</u>	28,43,892	<u>22,53,324</u>	40,65,401
		<u>148,72,87,496</u>		<u>137,75,02,182</u>
Additional Information :				
Details of revenue from sale of Manufactured Goods :				
Liquid		73,71,69,650		71,16,60,076
Tablets		64,69,07,902		57,52,18,479
Capsules		13,45,12,367		10,87,53,911
Others		4,21,08,178		5,68,03,442
		<u>156,06,98,097</u>		<u>145,24,35,908</u>

Notes forming part of Balance Sheet as at 31st March, 2016 and Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016		31st March, 2015	
	₹	₹	₹	₹
18. REVENUE FROM OPERATIONS (Contd.)				
Details of revenue from sale of Traded Goods :				
Liquid		6,10,482		1,19,412
Tablets		64,37,465		31,20,127
Others		86,34,010		93,85,475
		<u>1,56,81,957</u>		<u>1,26,25,014</u>
19. OTHER INCOME				
(a) Interest Income		6,53,338		86,94,037
(b) Profit/(Loss) on sale of assets		1,66,375		(993)
(c) Other income		45,603		27,787
		<u>8,62,316</u>		<u>87,20,831</u>
20. COST OF MATERIALS CONSUMED				
(a) <u>Raw materials :</u>				
Opening Stock	3,31,20,906		2,50,49,603	
Add : Purchases	29,21,55,104		30,78,03,929	
	<u>32,52,76,010</u>		<u>33,28,53,532</u>	
Less : Closing Stock	3,01,22,519	29,51,53,491	3,31,20,906	29,97,32,626
(b) <u>Packing materials and consumables :</u>				
Opening Stock	2,73,19,485		2,42,12,563	
Add : Purchases	16,09,88,669		15,46,53,739	
	<u>18,83,08,154</u>		<u>17,88,66,302</u>	
Less : Closing Stock	3,35,52,798	15,47,55,356	2,73,19,485	15,15,46,817
		<u>44,99,08,847</u>		<u>45,12,79,443</u>
Details of materials consumed :				
Iodine		11,43,24,349		12,42,15,254
Others		33,55,84,498		32,70,64,189
		<u>44,99,08,847</u>		<u>45,12,79,443</u>
21. CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS				
<u>Opening Stock :</u>				
Finished Goods	15,13,72,131		13,57,94,718	
Work-in-progress	1,18,166		4,42,918	
Traded Goods	8,53,781	15,23,44,078	8,83,797	13,71,21,433
<u>Less : Closing Stock</u>				
Finished Goods	14,38,80,469		15,13,72,131	
Work-in-progress	79,12,387		1,18,166	
Traded Goods	22,34,947	15,40,27,803	8,53,781	15,23,44,078
		<u>(16,83,725)</u>		<u>(1,52,22,645)</u>

Notes forming part of Balance Sheet as at 31st March, 2016 and
Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016 ₹	31st March, 2015 ₹
22. ADDITIONAL INFORMATION :		
Details of Opening and Closing Stock of Finished Goods (Manufactured) :		
(a) <u>Opening Stock :</u>		
Liquid	6,37,18,091	5,71,72,520
Tablets	5,37,74,114	5,16,80,916
Capsules	2,83,80,562	1,87,40,047
Others	<u>54,99,364</u>	<u>82,01,235</u>
	<u>15,13,72,131</u>	<u>13,57,94,718</u>
<u>Closing Stock :</u>		
Liquid	5,65,65,930	6,37,18,091
Tablets	5,22,95,646	5,37,74,114
Capsules	2,10,84,319	2,83,80,562
Others	<u>1,39,34,574</u>	<u>54,99,364</u>
	<u>14,38,80,469</u>	<u>15,13,72,131</u>
(b) Details of Opening and Closing Stock of Traded Goods :		
<u>Opening Stock :</u>		
Liquid	2,90,418	81,777
Tablets	75,219	1,39,584
Capsules	NIL	6,755
Others	<u>4,88,144</u>	<u>6,55,681</u>
	<u>8,53,781</u>	<u>8,83,797</u>
<u>Closing Stock :</u>		
Liquid	7,54,755	2,90,418
Tablets	13,65,718	75,219
Others	<u>1,14,474</u>	<u>4,88,144</u>
	<u>22,34,947</u>	<u>8,53,781</u>
23. EMPLOYEE BENEFITS EXPENSES		
(a) Salaries & Wages	39,88,53,142	36,91,60,725
(b) Contribution to Provident and Other Funds	4,93,78,599	4,62,10,045
(c) Workmen and Staff Welfare Expenses	<u>1,43,78,187</u>	<u>1,28,18,660</u>
	<u>46,26,09,928</u>	<u>42,81,89,430</u>
24. FINANCE COSTS		
(a) Interest on Overdraft	3,89,14,679	3,08,87,237
(b) Interest on Term Loans	1,80,275	2,148
(c) Interest on Public Deposit Scheme	NIL	18,72,579
(d) Other Interest and Bank Charges [including exchange difference of ₹ 18,77,383 (PY ₹ 5,78,280)]	<u>1,08,26,286</u>	<u>73,42,710</u>
	<u>4,99,21,240</u>	<u>4,01,04,674</u>

Notes forming part of Balance Sheet as at 31st March, 2016 and Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016		31st March, 2015	
	₹	₹	₹	₹
25. RESEARCH AND DEVELOPMENT EXPENSES				
(i) In-house Research :				
(a) Salaries & Wages	83,36,454		77,16,518	
(b) Contribution to Provident and Other Funds	7,27,879		6,75,898	
(c) Consumable Stores	9,81,022		18,02,597	
(d) Travelling Expenses	91,077		1,48,656	
(e) Repairs & Renewals	5,85,092		1,83,832	
(f) Miscellaneous Expenses	6,00,526	1,13,22,050	1,01,405	1,06,28,906
(ii) Contribution to External Research Organisations		11,28,600		13,68,600
		<u>1,24,50,650</u>		<u>1,19,97,506</u>

Note :

The above does not include Depreciation and Amortisation of ₹ 9,09,557 (previous year ₹ 13,98,113) pertaining to Research and Development assets.

26. OTHER EXPENSES

(a) Freight and Handling	4,63,53,116		4,33,70,717	
(b) Insurance	48,21,353		37,80,806	
(c) Power and Fuel	3,78,42,239		3,90,45,130	
(d) Payment to Auditors	6,37,290		6,10,000	
(e) Publicity and Sales Promotion	47,54,601		75,97,678	
(f) Rates, Taxes and License fees	15,76,254		17,24,194	
(g) Excise duty	34,92,983		(4,20,811)	
(h) Rent	1,29,03,201		1,19,76,868	
(i) Bad Debt	2,02,802		NIL	
(j) Provision for Doubtful Debts	1,65,413		NIL	
(k) Conversion Charges	3,87,10,534		3,30,82,579	
(l) Commission to C & F Agents	2,91,06,628		2,40,02,504	
(m) Discount	3,22,84,972		3,58,31,337	
(n) Repairs - Machineries	44,02,640		51,39,785	
- Buildings	20,27,424		15,13,707	
- Others	21,80,862	86,10,926	17,05,922	83,59,414
(o) Sales Tax		10,12,54,662		9,68,44,967
(p) Travelling and Conveyance		8,69,12,103		6,94,43,452
(q) Miscellaneous Expenses		3,44,70,892		3,30,97,048
		<u>44,40,99,969</u>		<u>40,83,45,883</u>

27. EARNINGS PER SHARE

Earnings per share has been computed as under :

(a) Profit after taxation for the year	3,62,01,731	1,72,92,719
(b) Number of Ordinary Shares	66,75,543	66,75,543
(c) Earnings per share on profit after taxation (Face Value Rs. 10.00 per share)		
- Basic	5.42	2.59
- Diluted	5.42	2.59

Notes forming part of Balance Sheet as at 31st March, 2016 and
Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016 ₹	31st March, 2015 ₹
-----------------	------------------------------	-----------------------

28. CONTINGENT LIABILITIES AND COMMITMENTS
(to the extent not provided for)

(i) Contingent Liabilities :		
(a) Claims against the company not acknowledged as debt :		
n in respect of Income Tax matters (disputed)	43,17,790	43,17,790
n in respect of Central Excise Duty (disputed)	6,18,08,843	6,05,05,829
n in respect of Service Tax (disputed)	22,394	NIL
n in respect of Sales Tax matters (disputed)	5,13,509	5,13,509
(b) Guarantees	5,77,000	5,77,000
(ii) Commitments :		
Estimated amount of contracts remaining to be executed on capital account and not provided for (Net of Advance)	3,54,95,049	2,42,04,720

29. DETAILS OF PAYMENT TO AUDITORS

1 As Auditor	4,25,000	4,50,000
1 For Taxation Matters	1,00,000	75,000
1 For Certification & Other Services	1,12,290	85,000
	<u>6,37,290</u>	<u>6,10,000</u>

30. DISCLOSURES ON RELATED PARTIES

(a) Related Party :		
(i) Qasar Healthcare Private Limited - Subsidiary (Shareholding 99.5%)		
(ii) Key Managerial Personnel		
Name	Designation	
Shri Amit Kumar Sen	Managing Director	
Shri Debarshi Duttagupta	Managing Director	
Shri Nirjhar Mukhopadhyay	Secretary & Chief Compliance Officer	
Shri Subrata Ray	Chief Financial Officer	
(iii) Relative of Key Managerial Personnel		
Ms Satarupa Mukherjee	Sr. Executive-Corporate Affairs	
(b) Transactions with Related Party during the period :		
(i) Receivable from Qasar Healthcare Private Limited	₹ 91,25,893	
(ii) Total Remuneration paid to Key Managerial Personnel	₹ 1,12,53,967	
(iii) Total Remuneration paid to relative of Key Managerial Personnel	₹ 9,16,551	

31. VALUE OF IMPORTS (CIF VALUE)

Raw materials	₹ 1020.09 lakhs	₹ 1138.81 lakhs
---------------	-----------------	-----------------

32. VALUE OF IMPORTED AND INDIGENOUS RAW MATERIALS, PACKING MATERIALS & CONSUMABLES CONSUMED DURING THE YEAR 2015-2016

	31. 03. 2016 Amount (₹ in lakhs)	31. 03. 2016 % to Total	31. 03. 2015 Amount (₹ in lakhs)	31. 03. 2015 % to Total
(a) Imported	1060.04	23.56	1093.89	24.24
(b) Indigenous	3439.05	76.44	3418.90	75.76
	<u>4499.09</u>	<u>100</u>	<u>4512.79</u>	<u>100</u>

Notes forming part of Balance Sheet as at 31st March, 2016 and Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016 ₹	31st March, 2015 ₹
33. EXPENDITURE IN FOREIGN CURRENCIES (ON PAYMENT BASIS) :		
On account of other matters	18,926	2,13,582
34. EARNINGS IN FOREIGN CURRENCIES		
From Export	7,14,229	NIL
35. THE FOLLOWING DISCLOSURES ARE MADE FOR THE AMOUNTS DUE TO THE MICRO, SMALL AND MEDIUM ENTERPRISES :		
(a) Principal amount payable to suppliers at the year end	54,98,398	45,81,512
(b) Amount of interest paid by the Company in terms of Section 16 of the MSMED, alongwith the amount of the payment made to the supplier beyond the appointed day during the accounting year	NIL	NIL
(c) Amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED	NIL	NIL
(d) Amount of interest accrued and remaining unpaid at the end of the accounting year	12,12,141	10,82,656
36. COMPANY HAS ONLY ONE PRIMARY SEGMENT, i.e., PRODUCTION AND SALE OF PHARMACEUTICAL PRODUCTS. INFORMATION REGARDING SECONDARY SEGMENT, i.e., GEOGRAPHICAL AREA IS GIVEN BELOW :		
Sales – Domestic	157,56,65,825	146,50,60,922
Sales – Export	7,14,229	NIL

37. During the year 2014 - 2015 the Company had charged depreciation in keeping with the requirements of Schedule II to the Companies Act, 2013. Consequently, the estimated useful lives of certain fixed assets had been revised, where considered appropriate, in keeping with the provisions of Schedule II to the Companies Act, 2013 effective 1st April, 2014. Pursuant to the said revision in useful lives, the depreciation expense for the year ended 31st March, 2015 was higher and profit before tax was lower by ₹15.82 lakhs and the net book value aggregating ₹ 40.37 lakhs (net of deferred tax ₹ 19.31 lakhs) relating to fixed assets, where the revised useful lives had expired by 31st March, 2014, had been adjusted against opening balance of retained earnings as on 1st April, 2014.

38. Figures for the previous years have been rearranged and regrouped, wherever necessary.

Kolkata,
Dated, the 11th. August, 2016

Sd/- R. Mukherji, P. Roy, C. Addy,
S. C. Basu, S. K. Mukerjee,
Directors A. Banerjee, T. Raychaudhury
Managing Directors A. K. Sen, D. Duttagupta
Secretary & CCO N. Mukhopadhyay
Chief Financial Officer S. Ray

Independent Auditors' Report

To The Members of **EAST INDIA PHARMACEUTICAL WORKS LIMITED**

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of **EAST INDIA PHARMACEUTICAL WORKS LIMITED** (hereinafter referred to as "the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group"), comprising of the Consolidated Balance Sheet as at 31st March, 2016, the Consolidated Statement of Profit and Loss, the Consolidated Cash Flow Statement for the year then ended, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

Management's Responsibility for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation of these consolidated financial statements in terms of the requirements of the Companies Act, 2013 (hereinafter referred to as "the Act") that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. While conducting the audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Holding Company's preparation of the consolidated financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on whether the Holding Company has an adequate internal financial controls system over financial reporting in place and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Holding Company's Board of Directors, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Auditors' Report

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at 31st March, 2016 and their consolidated profit and their consolidated cash flows for the year ended on that date.

Other Matters

Financial statements of the subsidiary, which reflect asset of Rs. 0.59 lacs as at 31st March, 2016, loss of Rs. 0.36 lacs and net cash flow of Rs. 0.36 lacs for the year then ended, have been audited by us.

Report on Other Legal and Regulatory Requirements

As required by Section 143(3) of the Act, we report that :

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
- b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books
- c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
- d) In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors of the Holding Company as on 31st March, 2016 taken on record by the Board of Directors of the Holding Company and our report of its subsidiary company, none of the directors of the Group companies is disqualified as on 31st March, 2016 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) We give in the Annexure a report on the internal financial control which is based on the auditors' report of the holding company and its subsidiary company.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i) The Group does not have any pending litigation which would impact the consolidated financial statements.
 - ii) The Group did not have any long term contract including derivative contracts for which there are any material foreseeable losses on long-term contracts including derivative contracts.
 - iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

Kolkata,
Dated, the 11th August, 2016

For APS ASSOCIATES
CHARTERED ACCOUNTANTS
(Registration No. 306015E)
(A.Dutta)
Partner
Membership No.017693

Auditors' Report

Annexure to the Independent Auditors' Report of even date on the Consolidated Financial Statements of East India Pharmaceutical Works Limited

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **East India Pharmaceutical Works Limited** ("the Holding Company") and its subsidiary (together referred to as "the Group") as of March 31, 2016 in conjunction with our audit of the consolidated financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding Company and its subsidiary are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by these entities, considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Holding Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Group's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Auditors' Report

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Group has, in all material respects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2016, based on the internal control over financial reporting criteria established by these entities considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India.

Kolkata,
Dated, the 11th August, 2016

For APS ASSOCIATES
CHARTERED ACCOUNTANTS
(Registration No. 306015E)
(A.Dutta)
Partner
Membership No.017693

Consolidated Balance Sheet

AS AT 31ST MARCH, 2016

	Note No.	31st March, 2016 ₹	31st March, 2015 ₹
I. EQUITY AND LIABILITIES			
(1) Shareholders' Funds			
(a) Share Capital	2	6,67,45,179	6,67,45,179
(b) Reserves and Surplus	3	33,03,99,991	30,22,68,237
(2) Minority Interests			
		(45,344)	(45,161)
(3) Non-current Liabilities			
(a) Long-Term Borrowings	4	1,80,13,635	NIL
(b) Long-Term Provision	8A	4,56,61,000	4,46,40,000
(4) Current Liabilities			
(a) Short-Term Borrowings	5	24,53,53,648	22,06,52,850
(b) Trade Payables	6	27,50,20,562	26,59,32,902
(c) Other Current Liabilities	7	20,61,29,512	17,14,49,769
(d) Short-Term Provisions	8B	2,15,09,434	1,89,66,319
TOTAL		120,87,87,617	109,06,10,095
II. ASSETS			
(1) Non-Current Assets			
(a) Fixed Assets			
(i) Tangible Assets	9	9,55,26,338	10,11,39,467
(ii) Intangible Assets	9	22,87,616	32,50,532
(iii) Capital work-in-progress		6,27,11,030	44,22,129
(b) Deferred Tax Assets (net)	10	3,14,98,725	3,08,31,111
(c) Long-Term Loans and Advances	11	1,80,06,774	62,33,280
(2) Current Assets			
(a) Inventories	12	21,77,03,120	21,27,84,469
(b) Trade Receivables	13	57,52,47,933	55,25,64,663
(c) Cash and Cash Equivalents	14	15,28,05,279	12,70,48,027
(d) Short-Term Loans and Advances	15	5,10,00,802	5,03,36,417
(e) Other Current Assets	16	20,00,000	20,00,000
TOTAL		120,87,87,617	109,06,10,095
Significant Accounting Policies	1		

The accompanying notes numbered 1 – 37 form an integral part of the financial statements.

This is the Consolidated Balance Sheet referred to in our report of even date.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693
Kolkata, Dated, the 11th. August, 2016

Sd/- R. Mukherji, P. Roy, C. Addy,
S. C. Basu, S. K. Mukerjee,
Directors A. Banerjee, T. Raychaudhury
Managing Directors A. K. Sen, D. Duttagupta
Secretary & CCO N. Mukhopadhyay
Chief Financial Officer S. Ray
Kolkata, Dated, the 11th. August, 2016

Consolidated Statement of Profit and Loss

FOR THE YEAR ENDED 31ST MARCH, 2016

	Note No.	31st March, 2016		31st March, 2015	
		₹	₹	₹	₹
I. REVENUE FROM OPERATIONS					
Revenue from Sales	17	157,63,80,054		146,50,60,922	
Less : Excise Duty		(9,19,36,450)	148,44,43,604	(9,16,24,141)	137,34,36,781
Other Operating Revenues	17		28,43,892		40,65,401
II. OTHER INCOME	18		8,62,316		87,20,831
III. TOTAL REVENUE (I + II)			148,81,49,812		138,62,23,013
IV. EXPENSES :					
Cost of materials consumed	19		44,99,08,847		45,12,79,443
Purchases of Traded Goods			74,93,699		40,64,883
Changes in inventories of finished goods, work-in-progress and Traded Goods	20		(16,83,725)		(1,52,22,645)
Employee benefits expenses	22		46,26,09,928		42,81,89,430
Finance Costs	23		4,99,21,557		4,01,04,972
Depreciation and amortization Expenses			1,43,58,909		1,63,34,235
Research and Development expenses	24		1,24,50,650		1,19,97,506
Other expenses	25		44,41,36,293		40,83,80,785
Total Expenses			143,91,96,158		134,51,28,609
V. PROFIT BEFORE TAX (III – IV)			4,89,53,654		4,10,94,404
VI. TAX EXPENSE :					
(1) Current tax		1,30,00,000		1,00,00,000	
(2) Deferred tax		(6,67,614)		(28,74,650)	
(3) Tax Adj. of earlier Years		4,56,178	1,27,88,564	1,67,11,535	2,38,36,885
VII. PROFIT FOR THE YEAR (V-VI)			3,61,65,090		1,72,57,519
VIII. EARNINGS PER EQUITY SHARE :	26				
(1) Basic			5.42		2.59
(2) Diluted			5.42		2.59

The accompanying notes numbered 1 – 37 form an integral part of the financial statements.

This is the Consolidated Statement of Profit and Loss referred to in our report of even date.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693
Kolkata, Dated, the 11th. August, 2016

Sd/- R. Mukherji, P. Roy, C. Addy,
S. C. Basu, S. K. Mukerjee,
Directors
A. Banerjee, T. Raychaudhury
Managing Directors
A. K. Sen, D. Duttagupta
Secretary & CCO
N. Mukhopadhyay
Chief Financial Officer
S. Ray
Kolkata, Dated, the 11th. August, 2016

Consolidated Cash Flow Statement

FOR THE YEAR ENDED 31ST MARCH, 2016

	31st March,2016 ₹	31st March,2015 ₹
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax & extraordinary items	4,89,53,654	4,10,94,404
Adjustments For :		
Depreciation / Amortisation	1,43,58,909	1,63,34,235
(Profit)/ Loss on sale of Fixed Assets	(1,66,375)	993
Interest Received	(6,53,338)	(86,94,037)
Interest Paid	4,99,21,240	4,01,04,972
Operating Profit before working capital changes	11,24,14,090	8,88,40,567
(Increase)/Decrease in Inventories	(49,18,651)	(2,64,00,870)
(Increase)/Decrease in Trade & Other Receivables	(3,51,21,149)	(20,07,449)
Increase/ (Decrease) in Trade & Other Payables	3,29,03,006	2,80,06,150
Cash generated from operations	10,52,77,296	8,84,38,398
Direct Tax paid	(1,01,52,063)	(2,41,48,622)
Net Cash Flow from Operating Activities	9,51,25,233	6,42,89,776
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(6,69,22,390)	(88,32,669)
Sale of Fixed Assets	10,17,000	22,000
Net Cash Flow from Investing Activities	(6,59,05,390)	(88,10,669)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from/(Repayment of) borrowings(net)	5,38,38,830	(23,67,004)
Payment of Dividend and Dividend Tax	(80,33,519)	(77,57,325)
Interest Paid	(4,99,21,240)	(4,01,04,972)
Interest Received	6,53,338	86,94,037
Net Cash Flow from Financing Activities	(34,62,591)	(4,15,35,264)
Net Cash Inflow (A+B+C)	2,57,57,252	1,39,43,843
Cash & Cash Equivalents - Opening	12,70,48,027	11,31,04,184
Cash & Cash Equivalents - Closing	15,28,05,279	12,70,48,027
	2,57,57,252	1,39,43,843

The accompanying notes numbered 1 – 37 form an integral part of the financial statements.

This is the Consolidated Cash Flow Statement referred to in our report of even date.

For APS ASSOCIATES
Chartered Accountants
(Registration No. 306015E)
(A. Dutta)
Partner
Membership No. 017693
Kolkata, Dated, the 11th. August, 2016

Sd/- R. Mukherji, P. Roy, C. Addy,
S. C. Basu, S. K. Mukerjee,
Directors A. Banerjee, T. Raychaudhury
Managing Directors A. K. Sen, D. Duttagupta
Secretary & CCO N. Mukhopadhyay
Chief Financial Officer S. Ray
Kolkata, Dated, the 11th. August, 2016

Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016

Note No.

1. Significant Accounting Policies

- (i) **Basis of preparation :**
The Consolidated Financial Statements have been prepared in accordance with the generally accepted accounting principles in India including the Accounting Standards notified under the relevant provisions of the Companies Act, 2013.
- (ii) **Principles of Consolidation :**
The Consolidated Financial Statements relate to East India Pharmaceutical Works Limited ('the company') and its subsidiary company, Qasar Health Care Private Limited. The Financial Statements of the Company and its subsidiary company are combined on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses, after fully eliminating intra-group balances and intra-group transactions in accordance with Accounting Standard (AS-21) - "Consolidated Financial Statements". Minority Interest's share, being negative have been adjusted with Consolidated Reserve and Surplus.
- (iii) **Revenue Recognition :**
All revenues are generally recognised on accrual basis. Gross sales is stated inclusive of Excise Duty, Sales Tax and VAT.
- (iv) **Fixed Assets :**
Fixed assets, including those utilised in R&D activities, are capitalised at cost of acquisition which includes freight, duties and taxes, incidental expenses and borrowing cost.
- (v) **Borrowing Costs :**
Borrowing costs are recognised as expense in the period in which they are incurred, except those directly attributable to the acquisition and construction of qualifying assets.
- (vi) **Depreciation :**
Depreciation is provided on the Written Down Value based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013.
- (vii) **Research and Development Expenses :**
Revenue expenditure on Research and Development is charged to revenue in the year in which it is incurred. Expenses of capital nature are capitalised.
- (viii) **Inventories :**
Inventories are valued at Lower of Cost and Net Realisable Value. Cost is determined as follows :

(a) Raw Materials	: Weighted average basis
(b) Work-in-Progress	: Weighted average basis
(c) Finished Goods	: Cost of input plus appropriate overhead
(d) Traded Goods	: Cost
(e) Packing materials and consumables	: Weighted average basis
- (ix) **Employee Benefits :**
Liabilities in respect of retirement benefits to employees are provided for as follows :
(I) **Defined Benefit Plans :**
(a) Leave encashment benefits are provided for on the basis of actuarial valuation.
(b) Superannuation Fund and Gratuity Fund on the basis of premium paid to the Life Insurance Corporation of India.
(II) **Defined Contribution Plans :**
Provident / Pension Fund and ESI on the basis of actual liability accrued and paid to Government Authorities.
- (x) **Foreign Currency Transaction :**
Transaction in foreign currencies are accounted for at exchange rates prevailing on the date of transaction. Gain / Loss arising on account of rise or fall in overseas currencies vis-a-vis reporting currency between the date of transaction and that of payment is charged to revenue.
- (xi) **Taxes on Income :**
Current Tax is determined as per the provisions of Income Tax Act, 1961. Deferred Tax liabilities/assets are recognised, subject to the consideration of prudence, on timing difference, being the difference between taxable income and accounting income.

Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016		31st March, 2015	
	₹	₹	₹	₹
2. SHARE CAPITAL				
(a) <u>Authorised :</u> 1,00,00,000 Ordinary Shares		10,00,00,000		10,00,00,000
(b) <u>Issued :</u> 66,75,543 Ordinary Shares		6,67,55,430		6,67,55,430
<u>Subscribed and paid up :</u> 66,74,858 Ordinary Shares fully called up		6,67,48,580		6,67,48,580
Less : Calls Unpaid		3,401		3,401
		6,67,45,179		6,67,45,179
(c) Par value per share		10.00		10.00
(d) <u>Quantitative Reconciliation :</u> Opening Balance as on 01.04.2015		66,74,518		66,74,518
Add : Shares issued during the year		NIL		NIL
Closing Balance as on 31.03.2016		66,74,518		66,74,518
(e) Shares held by each shareholder holding more than 5 percent shares specifying the number of shares held :				
<u>Name of the shareholder</u>		No. of shares		No. of shares
n Shri Amit Kumar Sen		6,43,918		6,43,918
n Shri Debarshi Duttagupta		6,50,019		6,50,019
(f) Aggregate number of shares allotted as fully paid-up bonus shares during the period of five years immediately preceding the date as at which the Balance Sheet is prepared		22,24,778		22,24,778
(g) Calls unpaid		3,401		3,401
1 Calls unpaid by Directors and Officers		NIL		NIL
3. RESERVES AND SURPLUS				
(a) General Reserve:				
Opening Balance	30,33,44,847		29,00,48,732	
Add: Adjustment for Depreciation (Refer Note No. 36)	NIL		40,36,915	
Add : Profit after tax for the year	3,62,01,731	33,95,46,578	1,72,92,719	31,13,78,366
Less : Provision for Dividend @ 10% (PY 10%)	66,74,518		66,74,518	
Provision for Dividend Distribution Tax	13,59,001	(80,33,519)	13,59,001	(80,33,519)
		33,15,13,059		30,33,44,847
Less : Share of loss from Subsidiary		(91,23,068)		(90,86,610)
		32,23,89,991		29,42,58,237
(b) Other Reserves:				
(i) Investment Fluctuation Reserve		10,000		10,000
(ii) Contingency Reserve		80,00,000		80,00,000
		33,03,99,991		30,22,68,237

Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016 ₹	31st March, 2015 ₹
4. LONG – TERM BORROWINGS		
Secured		
n Term Loan from United Bank of India (Repayable in Quarterly instalment and secured by hypothecation of specific assets procured under loan)	1,68,82,880	NIL
n Car Loan from HDFC Bank Ltd. (Repayable in equated monthly instalment and secured by against hypothecation of Vehieles)	11,30,755	NIL
	<u>1,80,13,635</u>	<u>NIL</u>
5. SHORT – TERM BORROWINGS		
Secured		
n From banks -		
n Cash Credit :		
1 From United Bank of India	24,53,53,648	22,06,52,850
Nature of Security :		
Secured by hypothecation of entire current assets of the Company with additional collaterals of charge over immovable properties.		
	<u>24,53,53,648</u>	<u>22,06,52,850</u>
6. TRADE PAYABLES		
Sundry Creditors	27,50,20,562	26,59,32,902
	<u>27,50,20,562</u>	<u>26,59,32,902</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016 ₹	31st March, 2015 ₹
7. OTHER CURRENT LIABILITIES		
(a) Current maturities of long-term Borrowings :		
n From banks -		
1 From United Bank of India (Repayable in Quarterly instalments and secured by hypothecation of specific assets procured under loan)	1,20,00,000	16,94,051
1 From HDFC Bank Ltd. (Repayable in equated monthly instalment and secured against hypothecation of Vehicles)	8,18,448	NIL
(b) Interest accrued and due on borrowings	3,24,107	7,74,275
(c) Unclaimed dividends *	95,79,359	1,10,25,770
(d) Other payables - (Includes Statutory Dues)	18,34,07,598	15,79,55,673
	<u>20,61,29,512</u>	<u>17,14,49,769</u>

* There are no amounts due and outstanding to be credited to Investor Education and Protection Fund.

8. PROVISIONS

A. Long Term Provision -		
Provision for Leave Encashment	<u>4,56,61,000</u>	<u>4,46,40,000</u>
B. Short Term Provision -		
(a) Provision for Leave Encashment	42,03,000	49,64,000
(b) Provision for Income Tax (Net of Advance Tax of ₹ 37,27,085, Previous Year ₹ 40,31,200)	92,72,915	59,68,800
(c) Provision for Proposed Dividend	66,74,518	66,74,518
(d) Provision for Tax on Proposed Dividend	13,59,001	13,59,001
	<u>2,15,09,434</u>	<u>1,89,66,319</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No. 9. FIXED ASSETS

Reconciliation of Gross and Net Carrying Amount of Each Class of Assets

Sl No	Particulars	Cost as on	Cost as on	Additions during the year	Deletions	Cost as on	Depreciation / Amortisation		Adjustment 2015-2016	Upto		Net Value as on March 31, 2016
		March 31, 2015	March 31, 2016			Upto March 31, 2015	For the year 2015-2016	Deletions 2015-2016		March 31, 2016	March 31, 2016	
		₹	₹	₹	₹	₹	₹	₹	₹	₹	₹	₹
TANGIBLE ASSETS												
(a)	Land	7,82,047	7,82,047	-	-	-	-	-	-	-	-	7,82,047
(b)	Buildings	8,83,40,694	8,83,40,694	-	-	4,65,76,298	25,30,476	-	-	4,91,06,774	-	3,92,33,920
(c)	Plant and Equipment*	28,69,21,465	29,09,90,246	40,68,781	-	23,89,46,968	67,09,668	-	-	24,56,56,636	-	4,53,33,610
(d)	Computer	64,05,296	68,58,523	4,53,227	-	58,46,258	3,50,536	-	-	61,96,794	-	6,61,729
(e)	Furniture and Fixture	2,29,29,407	2,36,10,711	6,81,304	-	1,90,64,489	10,22,236	-	-	2,00,86,725	-	35,23,986
(f)	Vehicles	1,70,14,514	1,56,64,049	30,14,063	43,64,528	1,32,30,331	18,03,474	35,13,901	-	1,15,19,904	-	41,44,145
(g)	Office Equipment	1,78,00,856	1,82,16,972	4,16,116	-	1,53,90,468	9,79,603	-	-	1,63,70,071	-	18,46,901
	Total	44,01,94,279	44,44,63,242	86,33,491	43,64,528	33,90,54,812	1,33,95,993	35,13,901	-	34,89,36,904	-	9,55,26,338
INTANGIBLE ASSETS												
	Copyrights, patents and other intellectual property rights, services and operating rights	1,56,47,278	1,56,47,278	-	-	1,23,96,746	9,62,916	-	-	1,33,59,662	-	22,87,616
	Total	1,56,47,278	1,56,47,278	-	-	1,23,96,746	9,62,916	-	-	1,33,59,662	-	22,87,616

*Includes additions to Research and Development assets : ₹ NIL (₹ 3,24,613)



Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No. 9. FIXED ASSETS (Contd)

Sl No	Particulars	Cost as on March 31, 2014 ₹	Additions during the year ₹	Deletions ₹	Cost as on March 31, 2015 ₹	Depreciation / Amortisation		Adjustment 2014-2015 ₹	Net Value as on March 31, 2015 ₹	
						Upto March 31, 2014 ₹	For the year 2014-2015 ₹		Upto March 31, 2015 ₹	March 31, 2015 ₹
TANGIBLE ASSETS										
(a)	Land	7,82,047	-	-	7,82,047	-	-	-	-	7,82,047
(b)	Buildings	8,69,11,150	14,29,544	-	8,83,40,694	4,46,63,823	27,03,880	7,91,405	4,65,76,298	4,17,64,396
(c)	Plant and Equipment*	28,33,33,039	35,88,426	-	28,69,21,465	23,62,48,950	77,44,828	50,46,810	23,89,46,968	4,79,74,497
(d)	Computer	61,09,661	2,95,635	-	64,05,296	53,79,000	4,18,643	-48,615	58,46,258	5,59,038
(e)	Furniture and Fixture	2,25,34,012	3,95,395	-	2,29,29,407	1,78,24,910	14,08,919	1,69,340	1,90,64,489	38,64,918
(f)	Vehicles	1,73,23,366	3,24,436	6,33,288	1,70,14,514	1,21,06,453	17,70,346	36,173	1,32,30,331	37,84,183
(g)	Office Equipment	1,74,72,969	3,27,887	-	1,78,00,856	1,44,47,046	9,15,922	(27,500)	1,53,90,468	24,10,388
	Total	43,44,66,244	63,61,323	6,33,288	44,01,94,279	33,06,70,182	1,49,62,537	59,67,613	33,90,54,812	10,11,39,467
INTANGIBLE ASSETS										
	Copyrights, patents and other intellectual property rights, services and operating rights	1,56,47,278	-	-	1,56,47,278	1,10,25,048	13,71,698	-	1,23,96,746	32,50,532
	Total	1,56,47,278	-	-	1,56,47,278	1,10,25,048	13,71,698	-	1,23,96,746	32,50,532

*Includes additions to Research and Development assets : ₹ 3,24,613 (₹ NIL)

1. Adjustment made consequent to revision of useful lives pursuant to Schedule II to the Companies Act, 2013. (Please refer Note 36)
2. Certain tangible assets have been regrouped, wherever possible, in line with Schedule II to the Companies Act, 2013.

Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016 ₹	31st March, 2014 ₹
10. DEFERRED TAX ASSETS (NET)		
Deferred Tax Liabilities :		
Depreciation as per Income Tax Act, 1961	6,42,96,936	6,00,70,939
Depreciation adjusted against Reserves and Surplus	19,30,697	19,30,697
Privilege Leave paid during the year	88,18,100	76,58,418
Research & Development Assets	1,02,98,155	1,02,98,155
Total (A)	<u>8,53,43,888</u>	<u>7,99,58,209</u>
Deferred Tax Assets :		
Depreciation charged in Accounts	9,09,91,432	8,62,38,633
Provision for Doubtful Debts	4,56,964	4,02,212
Provision for Leave Encashment for the year	2,53,94,217	2,41,48,475
Total (B)	<u>11,68,42,613</u>	<u>11,07,89,320</u>
Deferred Tax Asset (net) (B-A)	<u>3,14,98,725</u>	<u>3,08,31,111</u>
11. LONG – TERM LOANS AND ADVANCES (Unsecured, Considered Good)		
(a) Capital Advances	1,30,53,681	17,05,000
(b) Security Deposits	49,53,093	45,28,280
	<u>1,80,06,774</u>	<u>62,33,280</u>
12. INVENTORIES (At Lower of Cost and Net Realisable Value)		
(a) Raw materials	3,01,22,519	3,31,20,906
(b) Work-in-progress	79,12,387	1,18,166
(c) Finished Goods	14,38,80,469	15,13,72,131
(d) Traded Goods	22,34,947	8,53,781
(e) Packing materials and consumables	3,35,52,798	2,73,19,485
	<u>21,77,03,120</u>	<u>21,27,84,469</u>
The above includes goods in transit as under :		
(a) Raw materials	33,77,900	22,76,608
(b) Finished Goods	1,23,774	54,33,640
	<u>35,01,674</u>	<u>77,10,248</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	₹	31st March, 2016 ₹	₹	31st March, 2015 ₹
13. TRADE RECEIVABLES				
(i) Debts outstanding for a period exceeding six months :				
Unsecured, considered good		3,74,82,346		4,83,98,398
Unsecured, considered doubtful	56,88,362		55,22,949	
Less : Provision	<u>56,88,362</u>	NIL	<u>55,22,949</u>	NIL
(ii) Other Debts :				
Unsecured, considered good		53,77,65,587		50,41,66,265
		<u>57,52,47,933</u>		<u>55,25,64,663</u>
14. CASH AND CASH EQUIVALENTS				
(a) Cash and Cash Equivalents :				
n Cash in Hand		6,27,497		5,38,153
n Balances with Banks - In Current Accounts		14,25,83,423		11,33,87,795
(b) Other Bank Balances :				
n In Unclaimed Dividend Accounts		95,79,359		1,10,25,770
n In Fixed Deposit Accounts		15,000		20,96,309
		<u>15,28,05,279</u>		<u>12,70,48,027</u>
15. SHORT – TERM LOANS & ADVANCES (Unsecured, Considered Good)				
(a) Security Deposits		41,47,431		37,57,331
(b) Other advances		4,68,53,371		4,65,79,086
		<u>5,10,00,802</u>		<u>5,03,36,417</u>
16. OTHER CURRENT ASSETS Unsecured Considered Good				
Realisable from EPFO		20,00,000		20,00,000
		<u>20,00,000</u>		<u>20,00,000</u>
17. REVENUE FROM OPERATIONS				
(a) Revenue from Sales	157,63,80,054		146,50,60,922	
Less : Excise Duty	<u>(9,19,36,450)</u>	148,44,43,604	<u>(9,16,24,141)</u>	137,34,36,781
(b) Other operating revenues :				
n Claim	7,15,500		1,93,093	
n Refund of Excise Duty	NIL		39,706	
n Liabilities no longer required written back	NIL		15,79,278	
n Others	<u>21,28,392</u>	28,43,892	<u>22,53,324</u>	40,65,401
		<u>148,72,87,496</u>		<u>137,75,02,182</u>
Additional Information :				
Details of revenue from sale of Manufactured Goods :				
Liquid		73,71,69,650		71,16,60,076
Tablets		64,69,07,902		57,52,18,479
Capsules		13,45,12,367		10,87,53,911
Others		4,21,08,178		5,68,03,442
		<u>156,06,98,097</u>		<u>145,24,35,908</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016		31st March, 2015	
	₹	₹	₹	₹
17. REVENUE FROM OPERATIONS (Contd.)				
Details of revenue from sale of Traded Goods :				
Liquid		6,10,482		1,19,412
Tablets		64,37,465		31,20,127
Others		86,34,010		93,85,475
		<u>1,56,81,957</u>		<u>1,26,25,014</u>
18. OTHER INCOME				
(a) Interest Income		6,53,338		86,94,037
(b) Profit/(Loss) on sale of assets		1,66,375		(993)
(c) Other income		42,603		27,787
		<u>8,62,316</u>		<u>87,20,831</u>
19. COST OF MATERIALS CONSUMED				
(a) Raw materials :				
Opening Stock	3,31,20,906		2,50,49,603	
Add : Purchases	<u>29,21,55,104</u>		<u>30,78,03,929</u>	
	32,52,76,010		33,28,53,532	
Less : Closing Stock	<u>3,01,22,519</u>	29,51,53,491	<u>3,31,20,906</u>	29,97,32,626
(b) Packing materials and consumables :				
Opening Stock	2,73,19,485		2,42,12,563	
Add : Purchases	<u>16,09,88,669</u>		<u>15,46,53,739</u>	
	18,83,08,154		17,88,66,302	
Less : Closing Stock	<u>3,35,52,798</u>	15,47,55,356	<u>2,73,19,485</u>	15,15,46,817
		<u>44,99,08,847</u>		<u>45,12,79,443</u>
Details of materials consumed :				
Iodine		11,43,24,349		12,42,15,254
Others		33,55,84,498		32,70,64,189
		<u>44,99,08,847</u>		<u>45,12,79,443</u>
20. CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS				
Opening Stock :				
Finished Goods	15,13,72,131		13,57,94,718	
Work-in-progress	1,18,166		4,42,918	
Traded Goods	<u>8,53,781</u>	15,23,44,078	<u>8,83,797</u>	13,71,21,433
Less : Closing Stock				
Finished Goods	14,38,80,469		15,13,72,131	
Work-in-progress	79,12,387		1,18,166	
Traded Goods	<u>22,34,947</u>	15,40,27,803	<u>8,53,781</u>	15,23,44,078
		<u>(16,83,725)</u>		<u>(1,52,22,645)</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016 ₹	31st March, 2015 ₹
21. ADDITIONAL INFORMATION		
(a) Details of Opening and Closing Stock of Finished Goods (manufactured) :		
<u>Opening Stock :</u>		
Liquid	6,37,18,091	5,71,72,520
Tablets	5,37,74,114	5,16,80,916
Capsules	2,83,80,562	1,87,40,047
Others	54,99,364	82,01,235
	<u>15,13,72,131</u>	<u>13,57,94,718</u>
<u>Closing Stock :</u>		
Liquid	5,65,65,930	6,37,18,091
Tablets	5,22,95,646	5,37,74,114
Capsules	2,10,84,319	2,83,80,562
Others	1,39,34,574	54,99,364
	<u>14,38,80,469</u>	<u>15,13,72,131</u>
(b) Details of Opening and Closing Stock of Traded Goods :		
<u>Opening Stock :</u>		
Liquid	2,90,418	81,777
Tablets	75,219	1,39,584
Capsules	NIL	6,755
Others	4,88,144	6,55,681
	<u>8,53,781</u>	<u>8,83,797</u>
<u>Closing Stock :</u>		
Liquid	7,54,755	2,90,418
Tablets	13,65,718	75,219
Others	1,14,474	4,88,144
	<u>22,34,947</u>	<u>8,53,781</u>
22. EMPLOYEE BENEFITS EXPENSES		
(a) Salaries & Wages	39,88,53,142	36,91,60,725
(b) Contribution to Provident and Other Funds	4,93,78,599	4,62,10,045
(c) Workmen and Staff Welfare Expenses	1,43,78,187	1,28,18,660
	<u>46,26,09,928</u>	<u>42,81,89,430</u>
23. FINANCE COSTS		
(a) Interest on Overdraft	3,89,14,679	3,08,87,237
(b) Interest on Term Loans	1,80,275	2,148
(c) Interest on Public Deposit Scheme	NIL	18,72,579
(d) Other Interest and Bank Charges [including exchange difference of ₹ 18,77,383 (PY ₹ 5,78,280)]	1,08,26,603	73,43,008
	<u>4,99,21,557</u>	<u>4,01,04,972</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016		31st March, 2015	
	₹	₹	₹	₹
24. RESEARCH AND DEVELOPMENT EXPENSES				
(i) In-house Research :				
(a) Salaries & Wages	83,36,454		77,16,518	
(b) Contribution to Provident and Other Funds	7,27,879		6,75,898	
(c) Consumable Stores	9,81,022		18,02,597	
(d) Travelling Expenses	91,077		1,48,656	
(e) Repairs & Renewals	5,85,092		1,83,832	
(f) Miscellaneous Expenses	6,00,526	1,13,22,050	1,01,405	1,06,28,906
(ii) Contribution to External Research Organisations		11,28,600		13,68,600
		<u>1,24,50,650</u>		<u>1,19,97,506</u>

Note :

The above does not include Depreciation and Amortisation of ₹ 9,09,557 (previous year ₹ 13,98,113) pertaining to Research and Development assets.

25. OTHER EXPENSES

(a) Freight and Handling	4,63,53,116		4,33,70,717	
(b) Insurance	48,21,353		37,80,806	
(c) Power and Fuel	3,78,42,239		3,90,45,130	
(d) Payment to Auditors	6,39,590		6,12,280	
(e) Publicity and Sales Promotion	47,54,601		75,97,678	
(f) Rates, Taxes and License fees	15,91,904		17,27,444	
(g) Excise duty	34,92,983		-4,20,811	
(h) Rent	1,29,03,201		1,19,76,868	
(i) Bad Debt	2,05,071		NIL	
(j) Provision for Doubtful Debts	1,65,413		NIL	
(k) Conversion Charges	3,87,10,534		3,30,82,579	
(l) Commission to C & F Agents	2,91,06,628		2,40,02,504	
(m) Discount	3,22,84,972		3,58,31,337	
(n) Repairs - Machineries	44,02,640		51,39,785	
- Buildings	20,27,424		15,13,707	
- Others	21,80,862	86,10,926	17,05,922	83,59,414
(o) Sales Tax		10,12,54,662		9,68,44,967
(p) Travelling and Conveyance		8,69,12,103		6,94,43,452
(q) Miscellaneous Expenses		3,44,86,997		3,31,26,420
		<u>44,41,36,293</u>		<u>40,83,80,785</u>

26. EARNINGS PER SHARE

Earnings per share has been computed as under :

(a) Profit after taxation for the year	3,61,65,090	1,72,57,519
(b) Number of Ordinary Shares	66,75,543	66,75,543
(c) Earnings per share on profit after taxation (Face Value ₹ 10.00 per share)		
- Basic	5.42	2.59
- Diluted	5.42	2.59

Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016	31st March, 2015
	₹	₹

27. CONTINGENT LIABILITIES AND COMMITMENTS

(to the extent not provided for)

(i) Contingent Liabilities :

(a) Claims against the company not acknowledged as debt :		
n in respect of Income Tax matters (disputed)	43,17,790	43,17,790
n in respect of Central Excise Duty (disputed)	6,18,08,843	6,05,05,829
n in respect of Service Tax (disputed)	22,394	NIL
n in respect of Sales Tax matters (disputed)	5,13,509	5,13,509
(b) Guarantees	5,77,000	5,77,000

(ii) Commitments :

(a) Estimated amount of contracts remaining to be executed on capital account and not provided for (Net of Advance)	3,54,95,049	2,42,04,720
---	--------------------	-------------

28. DETAILS OF PAYMENT TO AUDITORS

1 As Auditor	4,27,300	4,52,280
1 For Taxation Matters	1,00,000	75,000
1 For Certification & Other Services	1,12,290	85,000
	<u>6,39,590</u>	<u>6,12,280</u>

29. DISCLOSURES ON RELATED PARTIES

(a) Related Party :

(i) Qasar Healthcare Privet Limited - Subsidiary (shareholding 99.5%)

(ii) Key Managerial Personnel

<u>Name</u>	<u>Designation</u>
Shri Amit Kumar Sen	Managing Director
Shri Debarshi Duttagupta	Managing Director
Shri Nirjhar Mukhopadhyay	Secretary & Chief Compliance Officer
Shri Subrata Ray	Chief Financial Officer

(iii) Relative of Key Managerial Personnel

Ms Satarupa Mukherjee Sr. Executive-Corporate Affairs

(b) Transactions with Related Party during the period :

(i) Receivable from Qasar Healthcare Private Limited	₹ 91,25,893
(ii) Total Remuneration paid to Key Managerial Personnel	₹ 1,12,53,967
(iii) Total Remuneration paid to relative of Key Managerial Personnel	₹ 9,16,551

30. VALUE OF IMPORTS (CIF VALUE)

(a) Raw materials	₹ 1020.09 lakhs	₹ 1138.81 lakhs
-------------------	------------------------	-----------------

31. VALUE OF IMPORTED AND INDIGENOUS RAW MATERIALS, PACKING MATERIALS & CONSUMABLES CONSUMED DURING THE YEAR 2015-2016

	31. 03. 2016	31. 03. 2016	31. 03. 2015	31. 03. 2015
	Amount	% to Total	Amount	% to Total
	(₹ in lakhs)		(₹ in lakhs)	
(a) Imported	1060.04	23.56	1093.89	24.24
(b) Indigenous	3439.05	76.44	3418.90	75.76
	<u>4499.09</u>	<u>100</u>	<u>4512.79</u>	<u>100</u>

Notes forming part of Consolidated Balance Sheet as at 31st March, 2016 and Consolidated Statement of Profit and Loss for the year ended on 31st March, 2016 (contd.)

Note No.	31st March, 2016 ₹	31st March, 2015 ₹
32. EXPENDITURE IN FOREIGN CURRENCIES (ON PAYMENT BASIS) :		
On account of other matters	18,926	2,13,582
33. EARNINGS IN FOREIGN CURRENCIES		
From Export	7,14,229	NIL
34. THE FOLLOWING DISCLOSURES ARE MADE FOR THE AMOUNTS DUE TO THE MICRO, SMALL AND MEDIUM ENTERPRISES :		
(a) Principal amount payable to suppliers at the year end	54,98,398	45,81,512
(b) Amount of interest paid by the Company in terms of Section 16 of the MSMED, alongwith the amount of the payment made to the supplier beyond the appointed day during the accounting year	NIL	NIL
(c) Amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED	NIL	NIL
(d) Amount of interest accrued and remaining unpaid at the end of the accounting year	12,12,141	10,82,656
35. COMPANY HAS ONLY ONE PRIMARY SEGMENT, i.e., PRODUCTION AND SALE OF PHARMACEUTICAL PRODUCTS. INFORMATION REGARDING SECONDARY SEGMENT, i.e., GEOGRAPHICAL AREA IS GIVEN BELOW :		
Sales – Domestic	157,56,65,825	146,50,60,922
Sales – Export	7,14,229	NIL

36. During the year 2014-2015 the Company had charged depreciation in keeping with the requirements of Schedule II to the Companies Act, 2013. Consequently, the estimated useful lives of certain fixed assets had been revised, where considered appropriate, in keeping with the provisions of Schedule II to the Companies Act, 2013 effective 1st April, 2014. Pursuant to the said revision in useful lives, the depreciation expense for the year ended 31st March, 2015 was higher and profit before tax was lower by ₹ 15.82 lakhs and the net book value aggregating ₹ 40.37 lakhs (net of deferred tax ₹ 19.31 lakhs) relating to fixed assets, where the revised useful lives had expired by 31st March, 2014 had been adjusted against opening balance of retained earnings as on 1st April, 2014.

37. Figures for the previous years have been rearranged and regrouped, wherever necessary.

Kolkata,
Dated, the 11th. August, 2016

Sd/- R. Mukherji, P. Roy, C. Addy,
S. C. Basu, S. K. Mukerjee,
Directors A. Banerjee, T. Raychaudhury
Managing Directors A. K. Sen, D. Duttagupta
Secretary & CCO N. Mukhopadhyay
Chief Financial Officer S. Ray

Form AOC - 1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

**Statement containing salient features of the financial statement of subsidiaries/
Associate companies / joint ventures
Part "A": Subsidiaries**

Sl. No	Name of the Company	Financial year of the Subsidiary Company ended on	Country of Incorporation	Percentage of Shareholding	Reporting currency and Exchange Rate
1	Qasar Healthcare Private Limited	31.03.2016	India	99.50%	INR

Name of the Subsidiary	Share Capital	Reserve & Surplus	Total Liabilities	Total Assets	Investment	Turn-over	Profit Before Taxes	Provision for Taxation	Profit After Taxes	Proposed Dividend
Qasar Healthcare Private Limited	1,00,000	(91,68,912)	91,28,193	59,281	-	-	(36,641)	-	(36,641)	-

Part "B": Associates and Joint Ventures

The Company does not have any Associates or Joint Ventures, therefore statement pursuant to Section 129(3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures is not applicable.

For and on behalf of the Board of Directors

Place: Kolkata
Date: August 11, 2016

Sd/-Dr. Ranabir Mukherji
Chairman

East India Organisation

REGISTERED OFFICE

6, Nandalal Bose Sarani, Kolkata 700 071
Telephones : 2287 2262/3004/3007/3009/3041/2283 0709
Tele Fax : 91-33-22873852/22874289
E.mail : eastindia@eastindiapharma.org / cipwl@dataone.in
Website : www.eastindiapharma.org

FACTORIES

119, Biren Roy Road (West), Kolkata 700 061
Telephones : 2493 3135/3284/3384/3435/4283/6897
Tele Fax : 91-33-24937274
E.mail : eisf@eastindiapharma.org

Waria Road, Raturia
Durgapur 713 215
Telephones : 255 5813/6177
Tele Fax : 91-343-2555813
E.mail : eipwldgp@dte.vsnl.net.in

TRAINING CENTRE

102, Shyamaprosad Mukherjee Road
Kolkata 700 026
Telephone : 2455 2490

SALES OFFICES

	Telephones		Telephones
Assam		Maharashtra	
Nilamoni Phukan Path	(0361) 2340745	Mumbai	(022) 26848792
Christian Basti	2340746	202-203, Syndicate Chambers	
Guwahati - 781 005	2340747	2nd Floor, Swami Nityananda Road	
Tele Fax : 91-361-2340745		Andheri (E), Mumbai - 400 069	
E.mail : eipwl_guwahati@eastindiapharma.org		Fax : 91-22-26848790	
		E.mail : eipwl_mumbai@eastindiapharma.org	
Bihar		Pune	(020) 25678687
Jaintpur Kothi, Bank Road	(0612) 2219817	Yashwant Appartments	
Patna - 800 001		Lane No. 4, Prabhat Road	
Tele Fax : 91-612-2219178		Deccan Gymkhana, Pune - 411 004	
E.mail : eipwl_patna@eastindiapharma.org		Fax : 91-20-25672377	
		E.mail : eipwl_pune@eastindiapharma.org	
Chhattisgarh		Orissa	(0671) 2322175 2316782
Ward No. 27, B.U.Complex,	(0771) 4020220	Plot No. 1108	
Daldal Seoni Road,		Holding No. 417/C1	
Mowa,		Vikash Nagar, Badambari, Cuttack - 753 012	
Near Anant Vihar Colony,		Fax : 91-671-2326782	
Raipur - 492 001		E.mail : eipwl_cuttack@eastindiapharma.org	
E-mail : eipwl_raipur@eastindiapharma.org			
Delhi		Rajasthan	(0141) 2373292 2378341
3620/21 Netaji Subhas Marg	(011) 23262150	Bombay House Building	
Daryaganj,		Mirza Ismail Road	
New Delhi - 110 002	23283408	Jaipur - 302 001	
Tele Fax : 91-11-23273985	23277199	Tele Fax : 91-141-2373292	
E.mail : eipwl_delhi@eastindiapharma.org		E.mail : eipwl_jaipur@eastindiapharma.org	
Gujarat		Tamil Nadu	(044) 22385312
Loksatta New Building	(0265) 2432551	Plot No. 8, 1st Floor	
Nagarwada	09327242551	14th Cross Street Extn.	
Baroda - 390 001		Elumalai Nagar, New Colony,	
Fax : 91-265-2432551		Chromepet, Chennai - 600 044	
E.mail : eipwl_baroda@eastindiapharma.org		Tele Fax : 91-44-22380567	
		E.mail : eipwl_chennai@eastindiapharma.org	
Haryana		Talengana	(040) 27178915
105 The Mall,	(0171) 2643280	Industrial Plots No. 148, 149 & 150	
Ambala Cantt. - 133 001	2630277	I.D.A., Mallapur, Hyderabad - 500 076	
Fax : 91-171-4010402		Tele Fax : 91-40-27178430	
E.mail : eipwl_ambala@eastindiapharma.org		E.mail : eipwl_hyderabad@eastindiapharma.org	
Jharkhand		Uttar Pradesh	
3rd. Floor, Trikuta Hill,	(0651) 6900050	Lucknow	(0522) 2236251 2236371
Kadru Road,		No. 5, 4th Floor	
Ranchi - 834 002		Saran Chamber-1, 5 Park Road	
E-mail : eipwl_ranchi@eastindiapharma.org		Lucknow - 226 001	
		Tele Fax : 91-522-2235513	
		E.mail : eipwl_lucknow@eastindiapharma.org	
Karnataka		Varanasi	(0542) 2508625
1 Mandi Veerappa Lane	(080) 22222978	S-25/221-C1, First Floor, Rudra Vihar,	
Off. Silver Jubilee Park	22130676	Mahaveer Mandir Road,	
Bangalore - 560 002		Tajpur, Orderly Bazar,	
Tele Fax : 91-80-22235424		Varanasi - 221 002	
E.mail : eipwl_bangalore@eastindiapharma.org		E.mail : eipwl_varanasi@eastindiapharma.org	
Kerala		West Bengal	
Kenson Colony No. 9	(0484) 2351467	Kolkata	(033) 24060369 24061916
Door No. XLI/470		136, Pathakpara Road	
(Old No. 39/120)		Kolkata 700 060	
Krishnaswamy Road,		Tele Fax : 91-33-24061926	
Ernakulam, Cochin - 682 035		E.mail : eipwl_kolkata@eastindiapharma.org	
Fax : 91-484-2351467			
E.mail : eipwl_ernakulam@eastindiapharma.org		Siliguri	(0353) 2502629 2502434
Madhya Pradesh		Burdwan Road	
746/1 Napier Town	(0761) 2450040	Siliguri - 734 005, Dt. Darjeeling	
Jabalpur - 482 001	4004622	Fax : 91-353-2502434	
Tele Fax : 91-761-4004622		E.mail : eipwl_siliguri@eastindiapharma.org	
E.mail : eipwl_jabalpur@eastindiapharma.org			

Names & Addresses of C & F Agents

as on 31st March, 2016

M/S A.C. SURGIPHARMA PVT. LTD.

K-59, Pratap Nagar
Delhi - 110 007
Phone No. : (011) 23693303, 23696719
Fax : 011-23697122
E-mail : us@acsurgipharma.com

M/S K. B. M. ENTERPRISES PVT. LTD.

Computer Zone Campus
Trimurti Place, Exhibition Road
Patna - 800 001
Phone No. : (0612) 2222448
E-mail : kbmenterprisespvtltd@yahoo.co.in

M/S MEHADIA & SONS

C/o Micropark Logistics Pvt. Ltd.
18th KM Stone, Opp. Deshonnati Press
Amravati Road, Gonkhedi
Nagpur - 440 023
Phone No. : (07118) 660355, 660356, 660340
Fax : 07118-660353
E-mail : eastindia.nagpur@mehadiagroup.com
eastindianagpur@gmail.com

M/S PAREKH INTEGRATED SERVICES PVT. LTD.

Circle - B - XXX, Plot No. 154, 1st Floor
Kailash Nagar, Focal Point Road, Sherpur
Ludhiana - 141 010 (PB)
Phone No. : (0161) 4621047, 4621048, 5012220
E-mail : parekh.ludhiana@pispl.in

M/S M.K.S. ENTERPRISES

Balajee Complex
Near Argon Battery, Tapovan, Kokar
Ranchi - 834 001
Phone No. : (0651) 25545971
Mobile No. : 9308789320
Fax : 0651-25545971
E-mail : eastindiaranchi@gmail.com

M/S VA DISTRIBUTORS

Plot No. 2, 1st. Floor, Room No. 1
Subburaya Nagar, Thiruneermalai Main Road,
Chrompet, Chennai - 600 044
Phone No. : (044) 22730001, 22730058
E-mail : plachennai@gmail.com
vaeast02@gmail.com

M/S S. K. LOGISTICS

1) City Link Warehousing Complex
Building No. B-3, Mumbai Nashik Highway
S. No. 120-121, Village - Vadape, Bhiwandi
Thane - 421 302
Phone No. : (02522) 307575
Fax : 02522-307500
E-mail : sklogistics@sk1932.com
2) 7, Mangal Das Road
Mumbai - 400 002

M/S VISHWANATH REMEDIES

P.O. Industrial Estate, G. T. Road
Chandpur, Lahartara
Varanasi - 221 106 (U.P.)
Phone No. : (0542) 2371060, 3291117
Fax : (0542) 39167338
E-mail : eastindia.varanasi@gmail.com

M/S BARODA CHEMIST PVT. LTD.

Ground Floor, Gheekanta
Ved Falia, Raopura
Vadodara - 390 001
Phone No. : (0265) 2410395, 2432270
E-mail : barodachemist@yahoo.com

M/S INDIAN SALES

Ward No. 27, B.U. Complex
Daldal Seoni Road, Mowa,
Raipur - 492 001 (C.G.)
Phone No. : (0771) 4020220
E-mail : indiansalesryp@gmail.com

M/S RUCHI MEDICAL Pvt. Ltd.

18, P. D. Tandon Marg
Laxman Chowk
Dehradun - 248 001
Uttaranchal
Phone No. : (0135) 2722640, 3202400
Tele Fax : 0135-2624933
E-mail : ruchimed@yahoo.com

M/S M. M. ASSOCIATES

E - 207, Transport Nagar
Lucknow - 226 012, U.P.
Phone No. : (0522) 4010547
Fax : 0522-4010546
E-mail : eipwllkocfa@gmail.com

M/S JAGOTA & SONS PVT. LTD.

Khasra No. 671-672
Opp. Sainthi Petrol Pump (Bharat Petroleum)
N.H.-58, Meerut Road, Sainthi
Ghaziabad - 201 206
Phone No. : (0120) 2675060
E-mail : eastindia@jagotagroup.com

M/S J & J CORPORATION

9, Kenson Colony
Krishnaswami Road
Cochin - 682 035
Phone No. : (0484) 4031268
E-mail : eipwl_ernakulam@eastindiapharma.org

M/S SRI RAMAKRISHNA ENTERPRISES

Door No. 26-9-18/A, Rama Rao Street
Gandhinagar, Vijayawada - 520 003
Phone No. : (0866) 2422192,
Mobile No. : 09440636373
E-mail : srkmtvja001@yahoo.com